NOVEL BENZIMIDAZOLES AS CORTICOTROPIN RELEASE FACTOR ANTAGONISTS

Abstract: The present invention describes novel benzimidazoles of formula (I) wherein D is an aryl or heteroaryl group, or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Description: TITLE NOVEL BENZIMIDAZOLES AS CORTICOTROPIN RELEASE FACTOR ANTAGONINSTS FIELD OF THE INVENTION This invention relates to novel benzimidazoles, pharmaceutical compositions containing the same and methods of using same in the treatment of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing corticotropin releasing factor (CRF) , including but not limited to disorders induced or facilitated by CRF. BACKGROUND Corticotropin releasing factor, a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) -derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat . Acad. Sci . (USA) 80:4851 (1983); W. Vale et al., Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohisto-chemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec . Prog. Horm. Res . 39:245 (1983); G.F. Koob, Persp. Behav. Med. 2:39 (1985); E.B. De Souza et al., J. Neurosci . 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J.E. Blalock, Physiological Reviews 69:1 (1989); J.E. Morley, Life Sci . 41:527 (1987)]. Clinical data provides evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E.B. De Souza, Hosp. Practice 23:59 (1988)]. In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C.B. Nemeroff et al., Science 226:1342 (1984); CM. Banki et al., Am. J. Psychiatry 144:873 (1987); R.D. France et al., Biol . Psychiatry 28:86 (1988); M. Arato et al., Biol Psychiatry 25:355 (1989)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C.B. Nemeroff et al., Arch. Gen . Psychiatry 45:577 (1988)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P.W. Gold et al., Am J. Psychiatry 141:619 (1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984); P.W. Gold et al., New Eng. J. Med. 314:1129 (1986)]. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R.M. Sapolsky, Arch . Gen . Psychiatry 46:1047 (1989)]. There is preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al . , Neuropsychopharmacology 2:53 ( 1989 ) ] . There has also been a role postulated for CRF in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine/non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D.R. Britton et al., Life Sci . 31:363 (1982); C.W. Berridge and A.J. Dunn Regul . Peptides 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist α-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C.W. Berridge and A.J. Dunn, Horm. Behav. 21:393 (1987), Brain Research Reviews 15:71 (1990)]. Neurochemical , endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [K.T. Britton et al., Psychopharmacology 86:170 (1985); K.T. Britton et al., Psychopharmacology 94:306 (1988)] and in the acoustic startle test [N.R. Swerdlow et al., Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptor antagonist (Rol5-1788), which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of CRF [K.T. Britton et al., Psychopharmacol ogy 94:306 (1988)]. The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (α-helical CRF9-41) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G.F. Koob and K.T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E.B. De Souza and C.B. Nemeroff eds., CRC Press p221 (1990)] . In view of the above, efficacious and specific antagonists of CRF are desired as potentially valuable therapeutic agents for the treatment of psychiatric disorders and neurological diseases. It is thus desirable to discover new CRF antagonists. SUMMARY OF THE INVENTION Accordingly, one object of the present invention is to provide novel benzimidazoles which are useful as CRF antagonists or pharmaceutically acceptable salts or prodrugs thereof . It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt form thereof. It is another object of the present invention to provide a method for treating psychiatric disorders and neurological diseases comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt form thereof. These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formula I: or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 2 , R 3 , R 7 , R 8 , X and D are defined below, are CRF antagonists . DETAILED DESCRIPTION OF THE INVENTION [1] Thus, in a first embodiment, the present invention provides a novel compound of formula I: (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 - 10 alkenyl, C2-10 alkynyl, C3-8 cycloalkyl, C3_6 cycloalkyl-Cι-6 alkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, -SO 2 -C 1 - 10 alkyl, -S0 2 -R la , and -S0 2 -R lb ; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 1 b , -COR 13a , -C0R 13a , -NR 15a C0R 13a , -N(C0R 13a ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 1 b , -C0NR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C3- 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R a , C0 2 R , COR and S0 2 R 14b ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc / Cι_ 6 alkyl, C 2 _s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, Cι- 4 haloalkyl, -OR 13a , -NR 13a R 16 , Cι_ alkoxy-Cι- 4 alkyl, and C 3 - 8 cycloalkyl which is substituted with 0- 1 R and in which 0-1 carbons of C 4 _ 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R l being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 -6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, Cχ_ 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl , isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR iS acOR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19a , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R , C0 2 R , COR and S0 2 R ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Cχ_ 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 1 b , -COR 13 , -OC(0)R 14b , -NR 15a COR 13 , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 14b , -NR 13a R 16 , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R a , C0 2 R 14b , COR 14b and S0R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl, - (CH 2 ) 1 - 4 -heteroaryl, or - (CH 2 ) _ 4 -heterocycle, wherein the aryl, heteroaryl, or heterocycle group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 Fs; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 - 8 cycloalkyl, Cι_ 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl ) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group Cι- 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 -.4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, Cχ- 6 alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Cι_ιo alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, Cι_ 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, aryl, aryl(Cι-4 alkyl)-, heteroaryl and heteroaryl (Ci- 4 alkyl)-; R 13 and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 _ 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group Cι_ 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C3_6 cycloalkyl-C -6 alkyl, aryl, aryl (C1-4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy Cι_ 4 haloalkoxy, and dimethylamino; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, Cι_ 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 1 b is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, Cι_ 4 alkoxy-Cι_ 4 alkyl, C 3 -6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-C -6 alkyl; R i7 is selected at each occurrence from the group H, Cι- 6 alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, C1- 4 haloalkyl, R 14 S (0) r .-Ci_.i alkyl, and R 17b 39b N-C 6 -4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, C 1 -6 alkyl, C3-10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι_ 2 alkyl, and C 1 - 4 haloalkyl; 17 19 17 19 alternatively, in an R moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and SO 2 R 14 ; alternatively, in an NR '^R 1 ' moiety, R" and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R "13 , C0 2 R 14 , COR 14 and S0 2 R i4 ; R 17 and R 19a are independently selected at each occurrence from the group H, Cχ- 6 alkyl, C3- 1 0 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl and C1-4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cχ_ 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, Cι_ haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 / -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 C0R 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C Fs, OCF 3 , S0 2 Me and acetyl; heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl , isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 1 a , COR 14 and S0 2 R 14a ; and, provided that when D is imidazole or triazole, R 1 is other than unsubstituted Cι- 6 linear or branched alkyl or C 3 - 6 cycloalkyl. [2a] In a more preferred embodiment, the present invention provides a novel compound of formula I, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ 6 alkyl, C _ 6 alkenyl, C 2 _ 6 alkynyl, C 3 -8 cycloalkyl, C3-8 cycloalkyl-Cι- 6 alkyl; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 1 b , -COR 13a , -C0 2 R 13a , and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group --00--, -S(0) n -, -NR 13a -, -NC0R 14b -, -NCOR 14b - and ,14b -NS0 2 R 1 R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 -8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -OR 13 , -NR 13 R 16a , C 1 -2 alkθ3y-Cι_ 2 alkyl, and 9 C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R l is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 19 , and -CONR 17 R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R , CO 2 R , COR and S0 2 R ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 ) 1 - 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 - 4 alkoxy; R 3 , R "7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl) 2 -amino; R 9 is independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C1-2 alkoxy-Ci- 2 alkyl, C3-6 cycloalkyl-Cι_ 2 alkyl, aryl (Ci_ 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl) -; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C3-6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 -6 alkyl; R 14 is selected from the group C 1 -. 4 alkyl, Cι_ 2 haloalkyl, Cι- 2 alkoxy-Cι- 2 alkyl, C 3 _6 cycloalkyl-Cι_ 2 alkyl, aryl(Cι_ 2 alkyl)-, and heteroaryl (Cι_ alkyl)-; R 1 a is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, Ci_ 2 alkoxy-Ci_ 2 alkyl, and C 3 - 6 cycloalkyl-Cι_ 2 alkyl; R 1 b is selected from the group C 1 - 4 alkyl, Cι- 2 haloalkyl, Cι- 2 alkoxy-Cι- 2 alkyl, C3-6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-2 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 _ 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C 1 -6 alkyl, C3- 1 0 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C 1 - 4 haloalkyl; 17 19 17 19 alternatively, in an NR R moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , CO 2 R 14 , COR 14 and SO 2 R 14 ; R 17a and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι_6 alkyl and C 1 - 4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group Cι- 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0R 18 , -NR 17 R 19 , and -CONR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl , isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2,3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15, C0 2 R 14a , COR 14a and S0 2 R 14a . [2b] In an even more preferred embodiment, the present invention provides a novel compound of formula I, wherein: X is selected from the group 0, S and a bond R 1 is selected from Cι_6 alkyl, C 3 - 8 cycloalkyl and C3-8 cycloalkyl-Cι-6 alkyl; R is substituted with 0-1 substituents selected from the group -CN, -C0 2 R 13a , and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C4-8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι- 6 alkyl, C _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , -OR 13a , -NR 13 R 16a , Ci_ 2 alkoxy-Cι- 2 alkyl, and C 3 - 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 _ 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 )2, OCH 2 CH2CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 )2/ -C(0)NH 2 , -C(0)NHCH 3 , and -C ( 0 ) N ( CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2/ CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 ) 1 - 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; R 3 and R 8 are independently selected at each occurrence from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CHCH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl , 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 / OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 . [2c] In a still more preferred embodiment, the present invention provides a novel compound of formula I, wherein: R 1 is substituted Ci; R is substituted with 0-1 substituents selected from the group -CN, -C0 2 CH 3 , and -CO 2 CH 2 CH 3 ; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CHOCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 - cyclobutyl, cyclopentyl, CH 3 -cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCHCH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 ; provided that R 1 is other than a - (CH 2 ) ι_ 4 -aryl or - (CH 2 ) ι_ 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH (01 3 ) 2 ; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C ( 0 ) N(CH 3 ) 2 . [2d] In a further preferred embodiment, the present invention provides a novel compound of formula I, wherein: R 1 is substituted (cyclopropyl) -Ci alkyl or (cyclobutyl) -Ci alkyl; R 1 is substituted with 0-1 -CN; R 1 is also substituted with 0-1 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH2CH2CH3, -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl ; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH3, OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [2e] In another further preferred embodiment, the present invention provides a novel compound of formula I, wherein: R 1 is (cyclopropyl )Cι alkyl or (cyclobutyl) -Ci alkyl substituted with 1 substituent independently selected at each occurrence from the group R l , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , Cl, F, and CF 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, and isoxazolyl, each heteroaryl being substituted on 0-2 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , OCH 3 , Cl, F, and CF 3 . [2f] In an even further preferred embodiment, the present invention provides a novel compound of formula I, wherein: R 1 is selected from the group (cyclopropyl )CH-CH 3 , (cyclopropyl ) CH-CH 2 CH 3 , (cyclopropyl ) CH-CHOCH 3 , (cyclopropyl) CH-CH 2 CH 2 CH 3 , (cyclopropyl ) CH-CH 2 CH 2 OCH , (cyclopropyl) 2 CH, phenyl (cyclopropyl)CH, furanyl (cyclopropyl )CH, thienyl (cyclopropyl) CH, isoxazolyl (cyclopropyl )CH, (CH 3 - furanyl) (cyclopropyl )CH, (cyclobutyl)CH-CH 3 , (cyclobutyl) CH-CH 2 CH 3 , (cyclobutyl ) CH-CH 2 OCH 3 , (cyclobutyl ) CH-CH 2 CH 2 CH 3 , (cyclobutyl ) CH-CH 2 CH 2 OCH 3 , (cyclobutyl) 2 CH, phenyl (cyclobutyl) CH, furanyl (cyclobutyl)CH, thienyl (cyclobutyl )CH, isoxazolyl (cyclobutyl)CH, and (CH 3 - furanyl ) (cyclobutyl ) CH; [2g] In another further preferred embodiment, the present invention provides a novel compound of formula I, wherein: D is phenyl substituted with 3-5 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [2h] In another further preferred embodiment, the present invention provides a novel compound of formula I, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [2i] In another preferred embodiment, R 1 is other than a cyclohexyl- (CH 2 )ι, 2 3, 4, 5, 6 , 7, 8 , 9 , or 10 - group; [2j]In another preferred embodiment, R 1 is other than an aryl-(CH 2 )ι, 2 , 3, 4, 5, 6, 7, 8, 9, or 10" group, wherein the aryl group is substituted or unsubstituted; [2k] In another preferred embodiment, R 1 is other than a heteroaryl- (CH )ι, 2 3, 4, 5, 6 , 1 , 8, 9, or 10- group, wherein the heteroaryl group is substituted or unsubstituted; [21] In another preferred embodiment, R 1 is other than a heterocyclyl- (CH 2 )ι, 2, 3, 4, 5, 6, 7, 8, 9, or 10- group, wherein the heterocyclyl group is substituted or unsubstituted. [2m] In another preferred embodiment, when D is imidazole or triazole, R 1 is other than unsubstituted Ci, 2 , 3 , 4 , 5, 6, 7, 8, 9, or 10 linear or branched alkyl or C3, 4, 5, 6, 7, or 8 cycloalkyl. [2n] In another preferred embodiment, R la is not substituted with OR 17 . [2o] In another preferred embodiment, the present invention provides a novel compound of formula I, wherein the compound is selected from: 1- (1-ethyl)propyl-2-ethyl-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-ethyl) propyl-2-methoxy-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, l-(l-methyl)butyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -7-methyl- lH-benzimidazole, 1- (l-methyl)butyl-2-methyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, l-(l-methyl) butyl-2-methoxy-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-butyl) -2-ethyl-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-carbmethoxy) propyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-carbethoxy) ethyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1, l-Dicyclopropyl)methyl-2-ethyl-4- (2, 4, 5-trichlorophenyl) - lH-benzimidazole, 1- (1, l-Dicyclopropyl)methyl-2-methoxy-4- (2,4,5- trichlorophenyl) -lH-benzimidazole, 1- (1-cyclopropyl) propyl-2-ethyl-4- (2 , 4, 5-trichlorophenyl) -1H- benzimidazole, l-cyclopentyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, l-cyclopentyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -6-methyl-1H- benzimidazole, 1- (1-phenyl) propyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1, 1-diphenyl) methyl-2-ethyl-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, l-cyclopentyl-2-ethyl-4- (2,4, 6-trimethylphenyl)benzimidazole, 1- (2-methyl) cyclopentyl-2-ethyl-4- (2 ,4, 6-trimethylphenyl) -1H- benzimidazole, 1- (1, l-dicyclopropyl)methyl-2-ethyl-4- (2,4, 6-trichlorophenyl) - lH-benzimidazole, 1- (1, 1-dicyclopropyl) methyl-2-ethyl-4- (2, 4-dichlorophenyl) -1H- benzimidazole, 1- (1, 1-dicyclopropyl )methyl-2-ethyl-4- (2-methyl-4- methoxyphenyl ) -lH-benzimidazole, 1- (1-cyclopropyl) butyl-2-ethyl-4- (2-methyl-4-methoxyphenyl) - IH- benzimidazole, 1- (3-pentyl) -2-ethyl-4- (2 , 4-dimethyl-5-fluorophenyl) -1H- benzimidazole, l-(2-pentyl)-2-ethyl-4- (2, 4-dimethyl-5-fluorophenyl )-lH- benzimidazole, 1- (2-methyl ) utyl-2-ethyl-4- (2 , 4-dichloro-5-fluorophenyl) -1H- benzimidazole, l-cyclopentyl-2-ethyl-4- (2,4, 6-trimethyl-3-pyridyl) -1H- benzimidazole, In another embodiment, the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt form thereof. In another embodiment, the present invention provides a method of treating psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart- related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in a mammal, comprising: administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof. In another embodiment, the present invention provides intermediate compounds useful in preparation of the CRF antagonist compounds and processes for making those intermediates, as described in the following description and claims. The CRF antagonist compounds provided by this invention and labelled derivatives thereof are also useful as standards and reagents in determining the ability of a potential pharmaceutical to bind to the CRF receptor. DEFINITIONS The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. The term "substituted, " as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14. When any variable (e.g., R^) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R 6 , then said group may optionally be substituted with up to two R 6 groups and R 6 at each occurrence is selected independently from the definition of R 6 . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds . As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C V F W where v = 1 to 3 and w = 1 to (2v+l) ) . Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl , pentafluoroethyl, and pentachloroethyl . "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl. "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counter-ion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7-to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3. O]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl . As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10- membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1. Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl , benzothiofuranyl , benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl , 2H, 6H-1 , 5 , 2-dithiazinyl , dihydrofuro[2,3-i»] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, liϊ-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,2,5- oxadiazolyl, 1,3, 4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl , phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl , tetrahydroisoquinolinyl , tetrahydroquinolinyl, 6H-1,2, 5-thiadiazinyl, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1, 2, 5-thiadiazolyl, 1,3,4- thiadiazolyl, thianthrenyl , thiazolyl, thienyl, thienothiazolyl , thienooxazolyl , thienoimidazolyl, thiophenyl, triazinyl, 1,2, 3-triazolyl, 1, 2,4-triazolyl, 1, 2, 5-triazolyl, 1,3,4-triazolyl, and xanthenyl . Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. "Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) , and the like. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an effective therapeutic agent. The term "therapeutically effective amount" of a compound of this invention means an amount effective to antagonize abnormal level of CRF or treat the symptoms of affective disorder, anxiety or depression in a host. SYNTHESIS The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Each of the references cited below are hereby incorporated herein by reference. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference. The novel benzimidazoles of Formulae (I) of this invention may be prepared by one of the general schemes outlined below (Schemes 1-2) . Compounds of Formulae (I) of this invention may be prepared as shown in Scheme I. An appropriately substituted 2-nitroaniline (II) is temporarily protected as the acetamide affording compounds of formula (III) . The acetate is shown as example and is not intended to limit the choice of protecting groups at this position. The acetamide formation is typically conducted in the presence of acetic anhydride, although acetyl chloride may also be utilized. The reaction may be conducted in a wide array of typically utilized organic solvents, however, methylene chloride is generally preferred. Subsequent nitration, most commonly with chilled fuming nitric acid, affords in excellent yield the dinitro acetamide (IV) . Details for this transformation may be found in the classical teachings of Vivian, etal . (J. Org. Chem. 1950, 20, 797) . Formation of compounds of formula (V) proceeds by hydrolysis of the acetamido group (see Green, T.W., Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York, NY, 1991, p.351) and functional group interconversion of the amine to the bromide via either a Sandmeyer reaction or Gatterman reaction via the intermediacy of the corresponding diazonium ion. One familiar in the art of organic synthesis will readily understand the optimal conditions necessary to effect this transformation, and may consult the text of March, J. {Advanced Organic Chemistry, John Wiley and Sons, Inc., New York, NY, 1985, p.570 and p.647). Compounds of formula (V) are reduced to the diamines of formula (VI) under a wide variety of potentially optimal conditions known to those skilled in the art. One may also consult the guide of Larock, R.C. ( Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, Inc., New York, NY, 1989, p.411) . The cyclized compounds of formula (VII) may be synthesized by treatment of diamines of formula (VI) with an ortho acid derivative of the formula (alkyl-O) 3C-X-R 2 where alkyl is preferably methyl, ethyl or propyl. The cyclizations are preferably carried out in the presence of an acid catalyst such as, but not limited to, hydrochloric acid, hydrobromic acid, nitric acid or an organic acid such as, but not limited to, propionic acid. The reactions are conducted at room temperature or optionally at elevated temperature up to boiling to effect loss of (alkyl-OH) from the reaction. Treatment of compounds of formula (VII) with a base and a compound of formula R 1 -X wherein X represents a leaving group may afford the desired benzimidazole compounds of formula (VIII) . Leaving groups may include, but are not limited to, bromo, chloro, iodo, cyano, alkoxy, methanesulfonyl, and p-toluenesulfonyl. Possible bases include, but are not limited to, the sodium, lithium or potassium bis (trimethylsilyl) amides, sodium or potassium hydride, alkyl lithiums and alkyl grignards and inorganic bases such as sodium, potassium and lithium hydroxide. The reactions are optionally conducted at room temperature or at elevated temperatures up to the boiling point of a cosolvent . A wide variety of inert solvents may be employed, for example, dimethylformamide, dimethylsulfoxide, toluene, tetrahydrofuran, diethyl ether, and methylene chloride. The reactions may be successfully performed in glass reaction vessels or polypropylene wells, and one skilled in the art of organic chemistry will readily understand the optimal combinations of above conditions for effecting this transformation. Although regiomeric alkylation products are conceivable from tautomers of formula (VII) , the experimental conditions taught herein will selectively provide the desired regiomer represented by compounds of formula (VIII) . Alternatively, compounds of formula (VIII) may be formed under the classic conditions of the Mitsunobu reaction (Synthesis, 1980, p.l) from compounds of formula (VII) and an alcohol R 1 -0H. Finally, the benzimidazoles of formula (I) may be formed from precursors of formula (VIII) by treatment with boronic acids of formula D-B(OH) 2 in the necessary presence of a palladium source, noteably Pd(OAc) 2 with the additives triphenyl-phosphine and sodium carbonate. The preferred solvent of the Suzuki coupling is dimethoxyethane, although other inert organic solvents such as diethyl ether, and tetrahydrofuran may also be employed. The reaction is effected at room temperature or at temperatures up to the boiling point of the solvent. One skilled in the art will understand optimized conditions as taught by Larsen, R.D. (J. Org. Chem. 1994, 54 , 6391-6394) . Alternatively, the benzimidazoles of formula (I) may also be prepared according to Scheme 2. A similiar teaching also appears in EP 0812831 ( vide supra) . Thus, under conditions taught in Scheme 1, the aryl bromides of formula (IX) are coupled to reagents of formula D-B(OH) to afford compounds of formula (X) . For the preparation of compounds of formula (IX) , one may refer to the art of Peet, etal. (J. Heterocyclic Chem. 1979, 16, 33-39) for details (R 3 =R 7 =R 8 =H) . Hydrolysis of the carboalkoxy of compounds of formula (X) under conditions familiar to anyone in the art affords the acid derivatives of formula (XI) which are then subjected to a modified Curtius rearrangement (see March, J., Advanced Organic Chemistry, John Wiley and Sons, Inc., New York, NY, 1985, p.984) in the presence of diphenylphosphoryl azide and a trialkyl amine base in an inert solvent (ie. dry benzene, dry- toluene) . The reaction is preferrably refluxed for one hour, cooled and treated with t-butanol and heated for an additional 2-24 hours to effect incorporation of the t- butyl carbamate, providing compounds of formula (XII, PG=Boc) . Reduction of compounds of formula (XII) under a wide variety of methods known to those skilled in the art affords cleanly the aryl diamines of formula (XIII) . Common reduction methods include hydrogenation in the presence of a catalyst such as Raney nickel (RaNi) or palladium on carbon (Pd/C) in an inert alcohol solvent (methanol, ethanol) or ethyl acetate. The reactions are optionally run under pressure and at elevated termperature (60°C) . Alternatively, and preferably, the reduction may be effected in exceptionally high yield by treatment of compounds of formula (XII) with sodium dithionite in the presence of ammonium hydroxide. One optimal solvent combination for this reduction is a mixture of dioxane/water (1:1) . Formation of compounds of formula (XIV) is achieved by a common reductive amination procedure employing compounds of formula (XIII) and the appropriate R 1 aldehydes and ketones. The reaction is preferably conducted under anhydrous conditions in the presence of a dehydrating agent (ie, sodium sulfate, magnesium sulfate) and acid catalyst (ie. hydrochloric acid, sulfuric acid, or acetic acid) . Examples of suitable reducing agents which are intended to exemplify and not limit the invention are sodium triacetoxyborohydride and sodium cyanoborohydride. Compounds of formula (XIV) are then deprotected under common conditions (PG = Boc, see, Green, T.W. Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York, NY, 1991, p.328) to afford pre- cyclization compounds of formula (XV) . Finally, the desired benzimidazoles of formula (I) are readily afforded from compounds of formula (XV) as described in Scheme 1 for the formation of (I) from compounds of formula (VIII) . SCHEME 1 D (III) (IV) (i) SCHEME 2 The following example is provided to describe the invention in further detail . The example, which sets forth the best mode presently contemplated for carrying out the invention, is intended to illustrate and not to limit the invention. EXAMPLE 1 2 -Ethγl- l- ( 1-ethvl-proDvl ) -4 - ( 2 . 4 . 5-trichloro- phenyl ) - lH-benz imidazole S en A: 2 ' ; 4 ' . 5 ' -Tri chl oro-3-ni tro-binhenvl-2-carboxvlJ r. aci d methyl es er Under a nitrogen atmosphere in 15 ml of anhydrous dimethoxyethane (DME) was dissolved 461 mg (1.76 mmol) triphenylphosphine. The reaction was evacuated and repressurized under nitrogen and stirred for 15 minutes at which point 98.55 mg of palladium acetate was added. The reaction was stirred for an additional 15 minutes at which point 1.10 g (4.88 mmol) of 2,4,5- trichlorophenylboronic acid was added. The reaction was stirred another 15 minutes at which time 1.14 g (4.39 mmol) of methyl 2-bromo-5-nitrobenzoate and 5 ml of 2N sodium carbonate were added. The reaction was evacuated and repressurized under nitrogen and heated to reflux for 18 hours at which time it was cooled, poured into 250 ml water, and extracted with ethyl acetate (3 x 50 ml) . The combined organic extracts were dried over magnesium sulfate, filtered and evaporated in vacuo to afford the crude product as a brown oil. The crude product was purified by column chromatography on silica gel (275 g) and eluted with 20% ethyl acetate in hexanes to afford 740 mg (47%) of the title compound. X H NMR (CDC1 3 ) 8.22 (dd, IH, J= 7 Hz, 1 Hz), 7.61 (m, 3H) , 7.41 (s, IH) , 3.74 (s, 3H) . Sten B : 2 ' , 4 ' , 5 ' -Trichloro-3-nitro-biphenyl-2-carboxylic acid Under a nitrogen atmosphere was combined 735 mg (2.03 mmol) of the title compound Step A, 5 ml of tetrahydrofuran (THF) , 3 ml of methanol, and 5 ml of water. To this solution was added 320 mg (8 mmol) of freshly powdered sodium hydroxide and the resulting solution was heated to reflux for 90 minutes. The reaction was cooled and concentrated in vacuo, diluted with 40 ml water and extracted with ethyl acetate (1 x 25 ml) . After separation the aqueous layer was acidified to pH < 2 with 6.25N hydrochloric acid (HC1) and extracted with ethyl acetate (3 x 25 ml) . The combined organic extracts from the acidified water layer were dried over magnesium sulfate, filtered, and concentrated in vacuo to yield 700 mg (100%) of the title compound. X H NMR (CDC1 3 ) 8.23 (dd, IH, J = 1 Hz, 1 Hz), 7.61 (m, 3H) , 7.26 (S, IH) . HRMS (M-H) ~ calcd for Cι 6 H 5 Cl 3 NιO 343.9284, found 343.9297. (2' ,4' , 5'-Trichloro-3-nitro-biphenyl-2-yl) -carbamic acid tert-butyl ester Under a nitrogen atmosphere in 20 ml of anhydrous benzene was combined 700 mg (2.03 mmol) of the title compound in Step B and 2.03 ml of triethylamine (TEA). To this solution was added 437 ml (2.03 mmol) of diphenylphosphoryl azide, and the resulting solution was heated to reflux for 1 hour. After completion the reaction mixture was cooled and 301 mg (4.06 mmol) of t- butanol was added, and the solution was heated to reflux for an additional 16 hours. The reaction mixture was concentrated in vacuo and purified by column chromatography on silica gel (200 g) and eluted using 20% ethyl acetate in hexanes to afford 502 mg (59%) of the title compound as a light yellow solid. E NMR (CDCI 3 ) 8 . 06 (dd , IH, J = 1 Hz , 1 . 5 Hz ) , 7 . 62 ( s , IH) , 7 . 49 (m, 3H) , 1 . 28 ( s , 9H) . HRMS (M-H ) ~ calcd for C 17 H 14 C1 3 N 2 0 415 . 0019 , found 415 . 0014 . (3-Amino-2' ,4' , 5' -trichloro-biphenyl-2-yl) -carbamic acid ert-butyl ester To 12 ml of a 1:1 solution of dioxane and water was added 500 mg (1.2 mmol) of the title compound in Step C and 0.6 ml of concentrated ammonium hydroxide. To this suspension was added 1.67 g (9.6 mmol) of sodium dithionite. The reaction mixture was stirred at room temperature for 2.5 hours and then concentrated in vacuo. The resulting oil was dissolved in 1:1 ethyl acetate and water and the layers separated. The aqueous layer was extracted with ethyl acetate (2 x 25 ml) and the combined organic extracts dried over magnesium sulfate, filtered, and evaporated to yield 536.6 mg (100%) of the title compound as a beige solid. IH NMR (DMSO d 6 ) 8.00 (br s, IH) , 7.80 (s, IH) , 7.40 (s, IH) , 6.98 (t, IH, J = 8 Hz), 6.74 (d, IH, J = 7.5 Hz) , 6.43 (d, IH, J = 7 Hz) , 1.16 (br s, 9H) . HRMS (M+H) + calcd for C 17 H 18 C1 3 N 2 0 2 387.0433 , found 387.0421. Step E: T3 (l-Ethyl-propylamino)-2' ,4' , 5 '-trichloro-biphenyl-2- vll -carbamic acid terfc-butvl ester Under a nitrogen atmosphere was combined 5 ml of acetic acid, 232 mg (0.6 mmol) of the title compound in Step D and 122 ml of 3-pentanone. To this solution was added 853 mg (6 mmol) of sodium sulfate. The solution was stirred at room temperature for 25 minutes at which time 153 mg (0.72 mmol) of sodiumtriacetoxyborohydride was added. The reaction was allowed to stir at room temperature for an additional 1 hour and then quenched with aqueous sodium carbonate (100 ml) and extracted with ethyl acetate (3 x 20 ml) . The combined organic extracts were dried over sodium sulfate, filtered, and evaporated to afford the crude product as a light brown oil. The crude product was purified by column chromatography on silica gel (30 g) and eluted with 20% ethyl acetate in hexanes to afford 171 mg (62%) of the title compound. X H NMR (CDC1 3 ) V.55 (s, IH) , 7,41 (br s, IH) , 7.21 (t, IH, J = 8 Hz), 6.71 (d, IH, J = 8 Hz), 6.46 (d, IH, J = 7 Hz), 3.32 (m, IH) , 1.58 (m, 4H) , 1.3 (s, 9H) , 0.9 (m, 6H) . HRMS (M + H) + calcd for C 22 H 28 C1 3 N 2 0 2 457.1216, found 457.1211. N-3- (1-EI-hyl -nropvla ino) -2 ' , 4 ' , 5 ' -trichloro-biphenvl- 2.3-diamine Under a nitrogen atmosphere was dissolved 171 mg (0.37 mmol) of the title compound in Step E in 1 ml of dichloromethane and the resulting solution chilled to 0°C. Trifluoroacetic acid (12 ml) was added dropwise over 4 minutes and the reaction stirred at 0°C for 1 hour and then allowed to warm to room temperature and stir for an additional 1 hour. Reaction was then evaporated in vacuo and the residual oil taken up in dichloromethane. The organic layer was washed with IN sodium hydroxide (1 x 25ml) and the layers separated. The aqueous layer was extracted with dichlormethane (2 x 25 ml) and the combined organic extracts dried over sodium sulfate filtered and evaporated to yield 129 mg (99%) of the product as a brown oil. X H NMR (CDCI 3 ) 7.62 (s, IH) , 7.46 (s, IH) , 6.86 (t, IH, J = 8 Hz) , 6.69 (d, IH, J = 7 Hz) , 6.48 (d, IH, J = 6 Hz) , 3.25 (m, IH) , 1.60 (m, 4H) , 0.95 (m, 6H) . HRMS (M+H) + calcd for Cι 7 H 20 Cl 3 N 2 357.0692, found 357.0693. Step fl; 2-Et vl -1 - M -Pfhvl-propvl) -4- (2,4. -trichloro-phenvl ) -1 H- benzimidazole Under a nitrogen atmosphere was combined 129 mg (0.36 mmol) of the title compound of Step F in 5 ml of triethylorthopropionate. To the resulting solution was added 2 drops of concentrated hydrochloric acid. The reaction was allowed to stir at room temperature for 8 hours and then poured into 100 ml of water. The reaction was extracted with ethyl acetate (4 x 20 ml) and the combined organic extracts dried over sodium sulfate, filtered, and evaporated to yield the crude product as a light brown crystal. The crude product was purified by column chromatography on silica gel (20 g) and eluted with 20% ethyl acetate in hexanes to yield 101 mg (71%) of the title compound as a brown solid. M.P. = 150.0- 151.5°C; H NMR (CDC1 3 ) 7.72 (s, IH) , 7.61 (s, IH) , 7.52 ( , IH) , 7.20 (m, 2H) , 4.10 (m, IH) , 2.92 (q, 2H, J= 8 Hz), 2.18 (m, 2H) , 2.05 (m, 2H) , 1.38 (t, 3H, J " = 8Hz) , 0.83 (t, 6H, J = 7.5 Hz); HRMS calc. for C 20 H 21 N 2 Cl 3 : (M+H) + 395.0849, Found 395.0846; Anal Calcd for C 20 H 21 N 2 Cl 3 : C, 60.70; H, 5.358; N,7.088. Found C, 60.40; H, 5.46; N, 6.75. The foregoing tables contain further examples which are meant to be illustrative of the present invention, and not to be taken as limiting thereof. TABLE 1 Ex. R 1 X R^ R J R' R a Mass Spec 1 CH(CH 2 CH 3 ) 2 CH 2 CH 3 H H H 395.09 2 CH(CH 2 CH 3 ) 2 CH 2 CH 3 CH 3 H H 3 CH(CH 2 CH 3 ) 2 CH 2 CH 3 H CH 3 H 4 CH(CH 2 CH 3 ) 2 CH 2 H H H H 5 CH(CH 2 CH 3 ) 2 0 CH 3 H H H 6 CH(CH 2 CH 3 ) 2 0 CH 3 H H CH 3 7 CH(CH 2 CH 3 ) 2 CH 2 CH 2 CH 3 H H H 8 CH(CH3)CH 2 CH 2 CH3 CH 2 CH 3 H CH 3 H 9 CH(CH 3 )CH 2 CH2CH 3 CH 2 H H H H 10 CH(CH 3 )CH 2 CH2CH3 0 CH 3 H H H 11 CH(CH3)CH2CH 2 CH 3 0 CH3 H H CH3 12 CH 2 CH 2 CH 3 CH 2 CH 3 H H H 13 CH 2 CH2CH2CH 3 CH 2 CH 3 H H H 14 CH 2 CH(CH 2 CH 3 )2 CH 2 CH 3 H H H 15 CH 2 CH 2 CH(CH3)2 CH 2 CH 3 H H H 16 CH(C0 2 CH 3 )CH2CH 3 CH 2 CH 3 H H H 17 CH(C0 2 CH 2 CH 3 )CH3 CH 2 CH 3 H H H 18 CH(COCH 3 )CH 2 CH 3 CH 2 CH 3 H H H 19 CH(COPh)CH 2 CH 3 CH 2 CH 3 H H H 20 CH 2 CH 2 C=CCH 3 CH 2 CH 3 H H H 21 CH(cyclo-Pr) 2 CH 2 CH 3 H H H 22 CH(cyclo-Pr) 2 CH 2 CH 3 CH 3 H H 23 CH(cyclo-Pr) 2 CH 2 CH 3 H CH 3 H 24 CH(cyclo-Pr) 2 CH 2 H H H H 25 CH(cyclo-Pr) 2 CH 2 H H CH 3 H 26 CH(cyclo-Pr) 2 0 CH 3 H H CH 3 27 CH(cyclo-Pr) 2 0 CH 3 H H H 28 CH(cyclo-Pr) 2 CH 2 CH 2 CH 3 H H H 29 CH 2 cyclopropyl CH 2 CH 3 H H H 30 CH 2 cyclopropyl CH 2 CH 3 CH 3 H H 31 CH 2 cyclopropyl CH 2 CH 3 H CH 3 H 32 CH(Et) (c-Pr) CH 2 CH 3 H H H 33 CH(Et) (c-Pr) CH 2 CH 3 CH 3 H H 34 CH(Et) (c-Pr) CH 2 CH 3 H CH 3 H 35 CH(Et) (c-Pr) CH 2 H H H H TABLE 1 (continued) Ex. X R' R b 36 CH 2 CH 2 OCH 2 CH 3 CH 2 CH 3 H H H 37 CH 2 CH 2 OCH 2 CH 3 CH 2 H H H H 38 CH 2 CH 2 OCH 2 CH 3 0 CH 3 H H H 39 cyclopentyl CH 2 CH 3 H H H 40 cyclopentyl CH 2 CH 3 Me H H 41 cyclohexyl CH 2 CH 3 H H H 42 cyclohexyl CH 2 CH 3 H Me H 43 CH 2 Ph CH 2 CH 3 H H H 44 CH 2 Ph 0 CH 3 H H H 45 CH(Ph)CH 2 CH 3 CH 2 CH3 H H H 46 CH(Ph) CH 2 CH3 H H H 47 CH 2 -(2-chloroPh) CH 2 CH 3 H H H 48 CH 2 -(4-chloroPh) CH 2 CH 3 H H H 49 CH 2 -(4-MeO-Ph) CH 2 CH 3 H H H 50 CH 2 -(4-CF 3 0-Ph) CH 2 CH 3 H H H TABLE 2 Ex. R 1 D 1 cyclopentyl 2,4, 6-trimethyl henyl 2 cyclohexyl 2,4, 6-trimethylphenyl 3 2-methyl (c-pentyl ) 2,4, 6-trimethylphenyl 4 benzyl 2,4, 6-trimethylphenyl 5 2-chlorobenzyl 2,4, 6-trimethylphenyl 6 4-chlorobenzyl 2,4, 6-trichlorophenyl 7 CH (cyclopropyl ) 2 2,4, 6-trichlorophenyl 8 4-fluorobenzyl 2 , 4-dichlorophenyl 9 CH (eyelopropy1 ) 2 2-chloro-4-bromophenyl 10 4-bromobenzy1 2-chloro-4-bromophenyl 11 4-methoxybenzyl 2-chloro-4-bromophenyl 12 CH (cyclopropyl ) 2 2-thiomethy1-4-bromopheny1 13 CH (eyelopropy1 ) 2-meth l-4-methoxyphenyl 14 CH(c-Pr)CH 2 CH 2 CH 3 2-methy1-4-methoxyphenyl 15 CH 2 CH 2 CH 2 CH 3 2 , 4-dimethyl-5-fluorophenyl 16 CH (CH 2 CH 3 ) 2 2 , 4-dimethyl-5-fluorophenyl 17 CH(CH 3 )CH 2 CH 2 CH 3 2 , 4-dimethyl-5-fluorophenyl 18 CH 2 CH(CH 3 )CH 2 CH 3 2 , 4-dichloro-5-fluorophenyl 19 CH 2 CH 2 OCH 2 CH 3 2 , 4-dichloro-5-fluorophenyl 20 CH(Ph) (C-Pr) 2-bromo-4-dimethylaminophenyl 21 CH(4-F-Ph) (C-Pr) 2-methyl-4-dimethylaminophenyl 22 cyclopentyl 2,4, 6-trimethyl-3-pyridyl 23 cyclohexyl 2,4,6-trimethyl-3-pyridyl 24 2-methyl (c-pentyl) 2,4, 6-trimethyl-3-pyridyl 25 benzyl 2,4, 6-trimethyl-3-pyridyl 26 CH(CH 2 CH 3 ) 2 2,4, 6-trimethyl-3-pyridyl 27 cyclopentyl 2 , 4-dimethyl-3-pyridyl 28 cyclohexyl 4,6-dimethyl-3-pyridyl 29 2-methyl (c-pentyl) 2 , 4-dimethoxy-3-pyridyl 30 benzyl 2-methyl-4-dimethylamino-3-pyridyl 31 2-methyl (c-pentyl) 6-methyl-4-dimethylamino-3-pyridyl 32 benzyl 2,4, 6-trimethyl-3, 5-pyrimidyl 33 CH(CH 2 CH 3 ) 2 2 , 4-dimethyl-3 , 5-pyrimidyl 34 cyclopentyl 4-isopropyl-2-furanyl 35 cyclohexyl 5-isopropyl-2-furanyl 36 2-methyl (c-pentyl) 4-isopropyl-2-thiophenyl 37 benzyl 5-isopropyl-2-thiophenyl TABLE 3 a 2 R 2 X=CH 3 S b 2 R 2 X=CH 3 S c 2 RX=CH 3 S a 3 R 2 X=Me b 3 R 2 X=Me c 3 R X=Me a 4 R 2 X=Et b 4 RX=Et c 4 R 2 X=Et a 5 R 2 X=n-Pr b 5 RX=n-Pr c 5 R 2 X=n-Pr di R X= =CH 3 0 d 2 R 2 X= =CH 3 S d 3 R 2 X= =Me d 4 R 2 X= =Et d 5 R 2 X= =n- Pr Ex.# Rl D 1 (cPr) 2 CH 2-Cl-4-MeO-phenyl 2 phenyl (cPr)CH 2-Cl-4-MeO-phenyl 3 2-furanyl(cPr)CH 2-Cl-4-MeO-phenyl 4 3-furan(cPr)CH 2-Cl-4-MeO-phenyl 5 2-thienyl(cPr)CH 2-Cl-4-MeO-phenyl 6 3-thienyl(cPr)CH 2-Cl-4-MeO-phenyl 7 2 -isoxazolyl (cPr ) CH 2-Cl-4-MeO-phenyl 8 2- (5-CH 3 - furanyl) (cPr)CH 2-Cl-4-MeO-phenyl 9 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-Cl-4-MeO-phenyl 10 cPr-CH(CH 3 ) 2-Cl-4-MeO-phenyl 11 l-cPr-CH(CH 2 CH 3 ) 2-Cl-4-MeO-phenyl 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-MeO-phenyl l-cPr-CH(CH OCH 3 ) 2-Cl-4-MeO-phenyl 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-Cl-4-MeO-phenyl (cBu) 2 CH 2 - C 1 - 4 -MeO - phenyl phenyl (cBu)CH 2 - C 1 - 4 -MeO - henyl 2-furanyl(cBu)CH 2-Cl-4-MeO-phenyl 3-furan(cBu)CH 2-Cl-4-MeO-phenyl 2-thienyl(cBu)CH 2-Cl-4-MeO-phenyl 3 - thienyl (cBu)CH 2 - C 1 - 4 -MeO - phenyl 2 -isoxazolyl (cBu) CH 2-Cl-4-MeO-phenyl 2- (5-CH 3 -f uranyl) (cBu)CH 2-Cl-4-MeO-phenyl 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 - C 1 - 4 -MeO - phenyl cBu-CH(CH 3 ) 2 - C 1 - 4 -MeO - phenyl l-cBu-CH(CH 2 CH 3 ) 2-Cl-4-MeO-phenyl 1-cBu-CH (CH 2 CH CH 3 ) 2-Cl-4-MeO-phenyl l-cBu-CH(CH 2 OCH 3 ) 2-Cl-4-MeO-phenyl l-cBu-CH(CH CH 2 OCH 3 ) 2-Cl-4-MeO-phenyl (cPr) 2 CH 2-Cl-4-CF 3 -phenyl phenyl (cPr)CH 2-Cl-4-CF 3 -phenyl 2- f uranyl (cPr)CH 2-Cl-4-CF 3 -phenyl 3-furan(cPr)CH 2-Cl-4-CF 3 -phenyl 2-thienyl(cPr)CH 2-Cl-4-CF3-phenyl 3-thienyl(cPr)CH 2-Cl-4-CF 3 -phenyl 2 -isoxazolyl (cPr)CH 2-Cl-4-CF 3 -phenyl 2- (5-CH 3 -furanyl) (cPr)CH 2-Cl-4-CF 3 -phenyl 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 -CI-4-CF3 -phenyl cPr-CH(CH 3 ) 2-Cl-4-CF 3 -phenyl l-cPr-CH(CH 2 CH 3 ) 2 -CI-4-CF3 -phenyl 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-CF 3 -phenyl l-cPr-CH(CH OCH 3 ) 2-Cl-4-CF 3 -phenyl 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-Cl-4-CF 3 -phenyl (cBu) 2 CH 2-Cl-4-CF 3 -phenyl phenyl (cBu)CH 2-Cl-4-CF 3 -phenyl 2- f uranyl (cBu)CH 2 -CI-4-CF3 -phenyl 3-furan(cBu)CH 2 -CI-4-CF3 -phenyl 2-thienyl(cBu)CH 2-Cl-4-CF 3 -phenyl 3-thienyl(cBu)CH 2-Cl-4-CF 3 -phenyl 2-isoxazolyl (cBu) CH 2-Cl-4-CF 3 -phenyl 2- (5-CH 3 -furanyl) (cBu)CH 2--Cl-4-CF 3 -phenyl 2-(4-CH 3 -isoxazolyl) (cBu)CH 2- -CI-4-CF 3 -phenyl cBu-CH(CH 3 ) 2- -CI-4-CF 3 -phenyl l-cBu-CH(CH 2 CH 3 ) 2- -Cl-4-CF 3 -phenyl l-cBu-CH(CH 2 CH 2 CH 3 ) 2- -Cl-4-CF 3 -phenyl l-cBu-CH(CH 2 OCH 3 ) 2- -Cl-4-CF 3 -phenyl 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2- -Cl-4-CF 3 -phenyl (cPr) 2 CH 2, 4-diCl-phenyl phenyl (cPr)CH 2, 4-diC1-phenyl 2-furanyl (cPr)CH 2, 4-diC1-phenyl 3-furan(cPr)CH 2, 4-diCl-phenyl 2-thienyl(cPr)CH 2, 4-diC1-phenyl 3-thienyl(cPr)CH 2 , 4-diCl-phenyl 2-isoxazolyl (cPr) CH 2 , 4-diCl-phenyl 2- (5-CH 3 -furanyl) (cPr)CH 2 , 4-diC1-phenyl 2-(4-CH 3 -isoxazolyl) (cPr)CH 2, 4-diCl-phenyl cPr-CH(CH 3 ) 2 4-diC1-phenyl l-cPr-CH(CH 2 CH 3 ) 2 4-diCl-phenyl 1-cPr-CH (CH 2 CH 2 CH 3 ) 2 4-diC1-phenyl l-cPr-CH(CH 2 OCH 3 ) 2 4-diCl-phenyl 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2 4-diCl-phenyl (cBu) 2 CH 2 4-diCl-phenyl phenyl (cBu)CH 2 , 4-diCl-phenyl 2-furanyl (cBu)CH 2 , 4-diCl-phenyl 3-furan(cBu)CH 2 , 4-diCl-phenyl 2-thienyl(cBu)CH 2 , 4-diCl-phenyl 3-thienyl(cBu)CH 2 , 4-diCl-phenyl 2-isoxazolyl (cBu) CH 2 , 4-diCl-phenyl 2- (5-CH 3 -furanyl) (cBu)CH 2 , 4-diCl-phenyl 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 , 4-diCl-phenyl cBu-CH(CH 3 ) 2 , 4-diCl-phenyl l-cBu-CH(CH 2 CH 3 ) 2 , 4-diCl-phenyl l-cBu-CH(CH 2 CH 2 CH 3 ) 2 , 4-diCl-phenyl l-cBu-CH(CH 2 OCH 3 ) 2 , 4-diCl-phenyl 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2 , 4-diCl-phenyl (cPr) 2 CH 2 , 5-diCl-phenyl phenyl (cPr)CH 2 , 5-diC1-phenyl 2-furanyl (cPr)CH 2 , 5-diCl-phenyl 88 3-furan(cPr)CH , 5-diCl-phenyl, 89 2-thienyl(cPr)CH , 5-diC1-phenyl 90 3-thienyl(cPr)CH :, 5-diCl-phenyl 91 2-isoxazolyl (cPr)CH :,5-diCl-phenyl 92 2- (5-CH 3 -furanyl) (cPr)CH , 5-diC1-phenyl 93 2-(4-CH 3 -isoxazolyl) (cPr)CH , 5-diCl-phenyl 94 cPr-CH(CH 3 ) : , 5-diCl-phenyl 95 l-cPr-CH(CH 2 CH 3 ) :, 5-diCl-phenyl 96 l-cPr-CH(CH 2 CH 2 CH 3 ) , 5-diCl-phenyl 97 l-cPr-CH(CH 2 OCH 3 ) ;, 5-diCl-phenyl 98 l-cPr-CH(CH 2 CH 2 OCH 3 ) :, 5-diCl-phenyl 99 (cBu) 2 CH :, 5-diCl-phenyl 100 phenyl (cBu)CH :,5-diCl-phenyl 101 2-furanyl (cBu)CH :, 5-diCl-phenyl 102 3-furan(cBu)CH :, 5-diCl-phenyl 103 2-thienyl (cBu)CH :,5-diCl-phenyl 104 3-thienyl (cBu)CH , 5-diCl-phenyl 105 2-isoxazolyl (cBu)CH :, 5-diC1-phenyl 106 2- (5-CH 3 -furanyl ) (cBu)CH :, 5-diC1-phenyl 107 2-(4-CH 3 -isoxazolyl) (cBu)CH :,5-diCl-phenyl 108 cBu-CH(CH 3 ) :, 5-diC1-phenyl 109 l-cBu-CH(CH 2 CH 3 ) :, 5-diCl-phenyl 110 l-cBu-CH(CH 2 CH 2 CH 3 ) , 5-diC1-phenyl 111 l-cBu-CH(CH 2 OCH 3 ) , 5-diCl-phenyl 112 l-cBu-CH(CH 2 CH 2 OCH 3 ) , 5-diCl-phenyl 113 (cPr) 2 CH 2-Cl-4-CF 3 0-phenyl 114 phenyl (cPr)CH 2-Cl-4-CF 3 0-phenyl 115 2-furanyl (cPr)CH 2-Cl-4-CF 3 0-phenyl 116 3-furan(cPr)CH 2-Cl-4-CF 3 0-phenyl 117 2-thienyl(cPr)CH 2-Cl-4-CF 3 0-phenyl 118 3-thienyl(cPr)CH 2-Cl-4-CF 3 0-phenyl 119 2-isoxazolyl (cPr)CH 2-Cl-4-CF 3 0-phenyl 120 2- (5-CH 3 -furanyl ) (cPr)CH 2-Cl-4-CF 3 0-phenyl 121 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-Cl-4-CF 3 0-phenyl 122 cPr-CH(CH 3 ) 2-Cl-4-CF 3 0-phenyl 123 l-cPr-CH(CH 2 CH 3 ) 2-Cl-4-CF 3 0-phenyl 124 l-cPr-CH(CHCHCH 3 ) 2-Cl-4-CF 3 0-phenyl 125 l-cPr-CH(CH 2 OCH 3 ) 2-Cl-4-CF 3 0-phenyl 126 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2-Cl-4-CF 3 0-phenyl 127 (cBu) CH 2-Cl-4-CF 3 0-phenyl 128 phenyl (cBu)CH 2-Cl-4-CF 3 0-phenyl 129 2- furanyl (cBu)CH 2-Cl-4-CF3θ-phenyl 130 3-furan(cBu)CH 2-Cl-4-CF 3 0-phenyl 131 2-thienyl(cBu)CH 2-Cl-4-CF 3 0-phenyl 132 3 -thienyl (cBu)CH 2-Cl-4-CF3θ-phenyl 133 2-isoxazolyl (cBu) CH 2-Cl-4-CF 3 0-phenyl 134 2- (5-CH 3 -f uranyl) (cBu)CH 2-Cl-4-CF 3 0-phenyl 135 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-Cl-4-CF 3 0-phenyl 136 cBu-CH(CH 3 ) 2-Cl-4-CF 3 0-phenyl 137 l-cBu-CH(CH 2 CH 3 ) 2-Cl-4-CF 3 0-phenyl 138 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-CF 3 0-phenyl 139 l-cBu-CH(CH 2 OCH 3 ) 2-Cl-4-CF 3 0-phenyl 140 l-cBu-CH(CH CH 2 OCH 3 ) 2-Cl-4-CF 3 0-phenyl 141 (cPr) 2 CH 2-Cl-4-CH 3 -phenyl 142 phenyl (cPr)CH 2-Cl-4-CH 3 -phenyl 143 2- f uranyl (cPr)CH 2-Cl-4-CH 3 -phenyl 144 3-furan(cPr)CH 2-Cl-4-CH 3 -phenyl 145 2-thienyl(cPr)CH 2 -CI-4-CH3 -phenyl 146 3-thienyl(cPr)CH 2-Cl-4-CH 3 -phenyl 147 2-isoxazolyl (cPr) CH 2-Cl-4-CH 3 -phenyl 148 2- (5-CH 3 -f uranyl) (cPr)CH 2-Cl-4-CH 3 -phenyl 149 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 -CI-4-CH3 -phenyl 150 cPr-CH(CH 3 ) 2-Cl-4-CH 3 -phenyl 151 l-cPr-CH(CH 2 CH 3 ) 2 -CI-4-CH3 -phenyl 152 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-CH 3 -phenyl 153 l-cPr-CH(CH 2 OCH 3 ) 2 -CI-4-CH3 -phenyl 154 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-Cl-4-CH 3 -phenyl 155 (cBu) 2 CH 2-Cl-4-CH 3 -phenyl 156 phenyl (cBu)CH 2-Cl-4-CH 3 -phenyl 157 2- furanyl (cBu)CH 2-Cl-4-CH 3 -phenyl 158 3-furan(cBu)CH 2-Cl-4-CH 3 -phenyl 159 2-thienyl(cBu)CH 2-Cl-4-CH 3 -phenyl 160 3- thienyl (cBu)CH 2-Cl-4-CH 3 -phenyl 161 2-isoxazolyl (cBu) CH 2 -CI-4-CH3 -phenyl 162 2- (5-CH 3 -f uranyl) (cBu)CH 2-Cl-4-CH 3 -phenyl 163 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-Cl-4-CH 3 -phenyl 164 cBu-CH(CH 3 ) 2-CI-4-CH 3 -phenyl 165 l-cBu-CH(CH 2 CH 3 ) 2-Cl-4-CH 3 -phenyl 166 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-CH 3 -phenyl 167 l-cBu-CH(CH 2 OCH 3 ) 2-CI-4-CH 3 -phenyl 168 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2-Cl-4-CH 3 -phenyl 169 (cPr) 2 CH 2-C1-4-CN- henyl 170 phenyl (cPr)CH 2-C1-4-CN-phenyl 171 2- f uranyl (cPr)CH 2-Cl-4-CN-phenyl 172 3-furan(cPr)CH 2-C1-4-CN-phenyl 173 2-thienyl(cPr)CH 2-C1-4-CN-phenyl 174 3-thienyl(cPr)CH 2-C1-4-CN-phenyl 175 2-isoxazolyl (cPr) CH 2-Cl-4-CN-phenyl 176 2- (5-CH 3 -f uranyl) (cPr)CH 2-Cl-4-CN-phenyl 177 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-Cl-4-CN-phenyl 178 cPr-CH(CH 3 ) 2-C1-4-CN-phenyl 179 l-cPr-CH(CH 2 CH 3 ) 2-Cl-4-CN-phenyl 180 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-CN-phenyl 181 l-cPr-CH(CH 2 OCH 3 ) 2-C1-4-CN-phenyl 182 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-C1-4-CN-phenyl 183 (cBu) 2 CH 2-Cl-4-CN-phenyl 184 phenyl (cBu)CH 2-Cl-4-CN-phenyl 185 2-furanyl(cBu)CH 2-C1-4-CN-phenyl 186 3-furan(cBu)CH 2-Cl-4-CN-phenyl 187 2-thienyl(cBu)CH 2-Cl-4-CN-phenyl 188 3 - thienyl (cBu)CH 2-C1-4-CN-phenyl 189 2-isoxazolyl (cBu) CH 2-Cl-4-CN-phenyl 190 2- (5-CH 3 -f uranyl) (cBu)CH 2-Cl-4-CN-phenyl 191 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-Cl-4-CN-phenyl 192 cBu-CH(CH 3 ) 2-C1-4-CN-phenyl 193 l-cBu-CH(CH CH 3 ) 2-Cl-4-CN-phenyl 194 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-C1-4-CN-phenyl 195 l-cBu-CH(CH 2 OCH 3 ) 2-C1-4-CN-phenyl 196 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2-Cl-4-CN-phenyl 197 (cPr) 2 CH 2-CF 3 -4-Cl-phenyl 198 phenyl (cPr)CH 2-CF 3 -4-Cl-phenyl 199 2-furanyl(cPr)CH 2-CF 3 -4-Cl-phenyl 200 3-furan(cPr)CH 2-CF 3 -4-Cl-phenyl 201 2-thienyl(cPr)CH 2-CF 3 -4-Cl-phenyl 202 3-thienyl(cPr)CH 2-CF 3 -4-Cl-phenyl 203 2-isoxazolyl (cPr) CH 2-CF 3 -4-Cl-phenyl 204 2- (5-CH 3 - furanyl) (cPr)CH 2-CF 3 -4-Cl-phenyl 205 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-CF 3 -4-Cl-phenyl 206 cPr-CH(CH 3 ) 2-CF 3 -4-Cl-phenyl 207 l-cPr-CH(CH 2 CH 3 ) 2-CF 3 -4-Cl-phenyl 208 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CF 3 -4-Cl-phenyl 209 l-cPr-CH(CH 2 OCH 3 ) 2-CF 3 -4-Cl-phenyl 210 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2-CF 3 -4-Cl-phenyl 211 (cBu) 2 CH 2-CF 3 -4-Cl-phenyl 212 phenyl (cBu)CH 2-CF 3 -4-Cl-phenyl 213 2- furanyl (cBu)CH 2-CF 3 -4-Cl-phenyl 214 3-furan(cBu)CH 2-CF 3 -4-Cl-phenyl 215 2-thienyl(cBu)CH 2-CF 3 -4-Cl-phenyl 216 3-thienyl(cBu)CH 2-CF 3 -4-Cl-phenyl 217 2-isoxazolyl (cBu) CH 2-CF 3 -4-Cl-phenyl 218 2- (5-CH 3 - furanyl) (cBu)CH 2-CF 3 -4-Cl-phenyl 219 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CF 3 -4-Cl-phenyl 220 cBu-CH (CH 3 ) 2-CF 3 -4-Cl-phenyl 221 l-cBu-CH(CH 2 CH 3 ) 2-CF 3 -4-Cl-phenyl 222 l-cBu-CH(CH 2 CH 2 CH 3 ) 2-CF 3 -4-Cl-phenyl 223 l-cBu-CH(CH 2 OCH 3 ) 2-CF 3 -4-Cl-phenyl 224 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2-CF 3 -4-Cl-phenyl 225 (cPr) 2 CH 2-CF 3 -4-MeO-phenyl 226 phenyl (cPr)CH 2-CF 3 -4-MeO-phenyl 227 2- furanyl (cPr)CH 2-CF 3 -4-MeO-phenyl 228 3-furan(cPr)CH 2-CF 3 -4-MeO-phenyl 229 2-thienyl(cPr)CH 2-CF 3 -4-MeO-phenyl 230 3-thienyl(cPr)CH 2-CF 3 -4-MeO-phenyl 231 2-isoxazolyl (cPr) CH 2-CF 3 -4-MeO-phenyl 232 2- (5-CH 3 - furanyl) (cPr)CH 2-CF 3 -4-MeO-phenyl 233 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-CF 3 -4-MeO-phenyl 234 cPr-CH(CH 3 ) 2-CF 3 -4-MeO-phenyl 235 l-cPr-CH(CH 2 CH 3 ) 2-CF 3 -4-MeO-phenyl 236 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CF 3 -4-MeO-phenyl 237 l-cPr-CH(CH 2 OCH 3 ) 2-CF 3 -4-MeO-phenyl 238 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-CF 3 -4-MeO-phenyl 239 (cBu) 2 CH 2-CF 3 -4-MeO-phenyl 240 phenyl (cBu)CH 2-CF 3 --4-MeO-phenyl 241 2 - furanyl ( cBu) CH 2-CF 3 - -4-MeO-phenyl 242 3-furan(cBu)CH 2-CF 3 - -4-MeO-phenyl 243 2-thienyl(cBu)CH 2-CF 3 - -4-MeO-phenyl 244 3-thienyl(cBu)CH 2-CF 3 - -4-MeO-phenyl 245 2-isoxazolyl (cBu) CH 2-CF 3 - -4-MeO- henyl 246 2- (5-CH 3 -furanyl) (cBu)CH 2-CF 3 - -4-MeO-phenyl 247 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CF 3 - -4-MeO-phenyl 248 cBu-CH(CH 3 ) 2-CF3 -4-MeO-phenyl 249 l-cBu-CH(CH 2 CH 3 ) 2-CF3 -4-MeO-phenyl 250 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-CF3 -4-MeO-phenyl 251 l-cBu-CH(CH 2 OCH 3 ) 2-CF3 -4-MeO-phenyl 252 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2-CF3 -4-MeO-phenyl 253 (cPr) 2 CH 2-CF3 -4-n-PrO-phenyl 254 phenyl (cPr)CH 2-CF3 -4-n-PrO-phenyl 255 2- furanyl (cPr)CH 2-CF3 -4-n-PrO-phenyl 256 3-furan(cPr)CH 2-CF3 -4-n-PrO-phenyl 257 2-thienyl(cPr)CH 2-CF3 -4-n-PrO-phenyl 258 3-thienyl(cPr)CH 2-CF3 -4-n-PrO-phenyl 259 2-isoxazolyl (cPr) CH 2-CF3 -4-n-PrO-phenyl 260 2- (5-CH 3 -furanyl) (cPr)CH 2-CF3 -4-n-PrO-phenyl 261 2- (4-CH3- isoxazolyl) (cPr)CH 2-CF3 -4-n-PrO-phenyl 262 cPr-CH(CH 3 ) 2-CF3 -4-n-PrO-phenyl 263 l-cPr-CH(CH 2 CH 3 ) 2-CF3 -4-n-PrO-phenyl 264 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CF3 -4-n-PrO-phenyl 265 l-cPr-CH(CH 2 OCH 3 ) 2-CF3 -4-n-PrO- henyl 266 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-CF3 -4-n-PrO-phenyl 267 (cBu) 2 CH 2-CF3 -4-n-PrO-phenyl 268 phenyl (cBu)CH 2-CF3 -4-n-PrO-phenyl 269 2 - furanyl ( cBu) CH 2-CF3 -4-n-PrO-phenyl 270 3-furan(cBu)CH 2-CF3 -4-n-PrO-phenyl 271 2-thienyl(cBu)CH 2-CF 3 -4-n-PrO-phenyl 272 3 - thienyl (cBu)CH 2-CF3 -4-n-PrO-phenyl 273 2-isoxazolyl (cBu) CH 2-CF3 -4-n-PrO-phenyl 274 2- (5-CH 3 -f uranyl) (cBu)CH 2-CF3 -4-n-PrO-phenyl 275 2- (4-CH3- isoxazolyl) (cBu)CH 2-CF3 -4-n-PrO-phenyl 276 cBu-CH(CH 3 ) 2-CF3 -4-n-PrO-phenyl 277 l-cBu-CH(CH 2 CH 3 ) 2-CF3 -4-n-PrO-phenyl 278 l-cBu-CH(CH 2 CH 2 CH 3 ) 2-CF3-4-n-PrO-phenyl 279 l-cBu-CH(CH 2 OCH 3 ) 2-CF 3 -4-n-PrO-phenyl 280 1-cBu-CH (CH CH 2 OCH 3 ) 2-CF 3 -4-n-PrO-phenyl 281 (cPr) 2 CH 2,4-diCF 3 -phenyl 282 phenyl (cPr)CH 2,4-diCF 3 -phenyl 283 2- f uranyl (cPr)CH 2,4-diCF 3 -phenyl 284 3-furan(cPr)CH 2,4-diCF 3 -phenyl 285 2-thienyl(cPr)CH 2,4-diCF 3 -phenyl 286 3-thienyl(cPr)CH 2,4-diCF 3 -phenyl 287 2-isoxazolyl (cPr) CH 2,4-diCF 3 -phenyl 288 2- (5-CH 3 - furanyl) (cPr)CH 2,4-diCF 3 -phenyl 289 2-(4-CH 3 -isoxazolyl) (cPr)CH 2,4-diCF 3 -phenyl 290 cPr-CH(CH 3 ) 2,4-diCF 3 -phenyl 291 l-cPr-CH(CH 2 CH 3 ) 2,4-diCF 3 -phenyl 292 l-cPr-CH(CH 2 CH 2 CH 3 ) 2, 4-diCF 3 -phenyl 293 l-cPr-CH(CH 2 OCH 3 ) 2,4-diCF 3 -phenyl 294 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2,4-diCF 3 -phenyl 295 (cBu) 2 CH 2,4-diCF 3 -phenyl 296 phenyl (cBu)CH 2,4-diCF 3 -phenyl 297 2- furanyl (cBu)CH 2,4-diCF 3 -phenyl 298 3-furan(cBu)CH 2,4-diCF 3 -phenyl 299 2-thienyl(cBu)CH 2,4-diCF 3 -phenyl 300 3-thienyl(cBu)CH 2,4-diCF 3 -phenyl 301 2-isoxazolyl (cBu) CH 2,4-diCF3-phenyl 302 2- (5-CH3- furanyl) (cBu)CH 2,4-diCF 3 -phenyl 303 2-(4-CH 3 -isoxazolyl) (cBu)CH 2,4-diCF 3 -phenyl 304 cBu-CH(CH 3 ) 2,4-diCF 3 -phenyl 305 l-cBu-CH(CH 2 CH 3 ) 2,4-diCF 3 -phenyl 306 l-cBu-CH(CH 2 CH 2 CH 3 ) 2,4-diCF 3 -phenyl 307 l-cBu-CH(CH 2 OCH 3 ) 2,4-diCF 3 -phenyl 308 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2, 4-diCF 3 -phenyl 309 (cPr) 2 CH 2-CF3-4-F-phenyl 310 phenyl (cPr)CH 2-CF 3 -4-F-phenyl 311 2-f uranyl (cPr)CH 2-CF 3 -4-F-phenyl 312 3-furan(cPr)CH 2-CF 3 -4-F-phenyl 313 2-thienyl(cPr)CH 2-CF 3 -4-F-phenyl 314 3-thienyl(cPr)CH 2-CF3-4-F-phenyl 315 2-isoxazolyl (cPr) CH 2-CF 3 -4-F-phenyl 316 2- (5-CH3- furanyl) (cPr)CH 2-CF 3 -4-F-phenyl 317 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-CF 3 -4-F-phenyl 318 cPr-CH(CH 3 ) 2-CF3-4-F-phenyl 319 l-cPr-CH(CH 2 CH 3 ) 2-CF3-4-F-phenyl 320 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CF3-4-F-phenyl 321 l-cPr-CH(CH 2 OCH 3 ) 2-CF3-4-F-phenyl 322 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2 -CF3 -4-F-phenyl 323 (cBu) CH 2-CF3-4-F-phenyl 324 phenyl (cBu)CH 2-CF3-4-F-phenyl 325 2 - furanyl ( cBu ) CH 2 -CF3 -4-F-phenyl 326 3-furan(cBu)CH 2 -CF3 -4-F-phenyl 327 2-thienyl(cBu)CH 2 -CF3- 4-F-phenyl 328 3-thienyl(cBu)CH 2 -CF3 -4-F-phenyl 329 2-isoxazolyl (cBu) CH 2-CF3-4-F-phenyl 330 2- (5-CH 3 -furanyl) (cBu)CH 2 -CF3 -4-F-phenyl 331 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CF3-4-F-phenyl 332 cBu-CH(CH 3 ) 2 -CF3 -4-F-phenyl 333 l-cBu-CH(CH 2 CH 3 ) 2 -CF3 -4-F-phenyl 334 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-CF3-4-F-phenyl 335 l-cBu-CH(CH 2 OCH 3 ) 2 -CF3 -4-F-phenyl 336 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2-CF3-4-F-phenyl 337 (cPr) 2 CH 2-CH 3 -4-Cl-phenyl 338 phenyl (cPr)CH 2-CH 3 -4-Cl-phenyl 339 2- f uranyl (cPr)CH 2-CH 3 -4-Cl-phenyl 340 3-furan(cPr)CH 2-CH 3 -4-Cl-phenyl 341 2-thienyl(cPr)CH 2-CH 3 -4-Cl-phenyl 342 3-thienyl(cPr)CH 2-CH 3 -4-Cl-phenyl 343 2-isoxazolyl (cPr) CH 2-CH 3 -4-Cl-phenyl 344 2- (5-CH 3 -f uranyl) (cPr)CH 2-CH 3 -4-Cl-phenyl 345 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-CH 3 -4-Cl-phenyl 346 cPr-CH(CH 3 ) 2-CH 3 -4-Cl-phenyl 347 l-cPr-CH(CH 2 CH 3 ) 2-CH 3 -4-Cl-phenyl 348 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CH 3 -4-Cl-phenyl 349 l-cPr-CH(CH 2 OCH 3 ) 2-CH 3 -4-Cl-phenyl 350 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2-CH 3 -4-Cl-phenyl 351 (cBu) 2 CH 2-CH 3 -4-Cl-phenyl 352 phenyl (cBu)CH 2-CH 3 -4-Cl-phenyl 353 2 - furanyl ( cBu ) CH 2-CH 3 -4-Cl-phenyl 354 3-furan(cBu)CH 2-CH 3 -4-Cl-phenyl 355 2 - thienyl (cBu)CH 2-CH 3 -4-Cl-phenyl 356 3-thienyl(cBu)CH 2-CH 3 -4-Cl-phenyl 357 2-isoxazolyl (cBu) CH 2-CH 3 -4-Cl-phenyl 358 2- (5-CH3- furanyl) (cBu)CH 2-CH 3 -4-Cl-phenyl 359 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CH 3 -4-Cl-phenyl 360 cBu-CH(CH 3 ) 2-CH 3 -4-Cl-phenyl 361 l-cBu-CH(CH 2 CH 3 ) 2-CH 3 -4-Cl-phenyl 362 l-cBu-CH(CH 2 CH 2 CH 3 ) 2-CH 3 -4-Cl-phenyl 363 l-cBu-CH(CH 2 OCH 3 ) 2-CH 3 -4-Cl-phenyl 364 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2-CH 3 -4-Cl-phenyl 365 (cPr) 2 CH 2-CH 3 -4-MeO-phenyl 366 phenyl (cPr)CH 2-CH 3 -4-MeO-phenyl 367 2- f uranyl (cPr)CH 2-CH 3 -4-MeO-phenyl 368 3-furan(cPr)CH 2-CH 3 -4-MeO-phenyl 369 2-thienyl(cPr)CH 2-CH 3 -4-MeO-phenyl 370 3-thienyl(cPr)CH 2-CH 3 -4-MeO-phenyl 371 2-isoxazolyl (cPr) CH 2-CH 3 -4-MeO-phenyl 372 2 - ( 5 -CH 3 - furanyl ) ( cPr ) CH 2-CH 3 -4-MeO-phenyl 373 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-CH 3 -4-MeO-phenyl 374 cPr-CH(CH 3 ) 2-CH 3 -4-MeO-phenyl 375 l-cPr-CH(CH 2 CH 3 ) 2 -CH3- 4 -MeO- phenyl 376 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CH 3 -4-MeO-phenyl 377 l-cPr-CH(CH 2 OCH 3 ) 2-CH 3 -4-MeO-phenyl 378 l-cPr-CH(CH 2 CH OCH 3 ) 2-CH 3 -4-MeO-phenyl 379 (cBu) 2 CH 2-CH 3 -4-MeO-phenyl 380 phenyl (cBu)CH 2-CH 3 -4-MeO-phenyl 381 2- furanyl (cBu)CH 2-CH 3 -4-MeO-phenyl 382 3-furan(cBu)CH 2-CH 3 -4-MeO-phenyl 383 2 - thienyl (cBu)CH 2-CH 3 -4-MeO-phenyl 384 3-thienyl(cBu)CH 2-CH 3 -4-MeO-phenyl 385 2-isoxazolyl (cBu) CH 2-CH 3 -4-MeO-phenyl 386 2- (5-CH 3 -f uranyl) (cBu)CH 2 -CH3- 4 -MeO- phenyl 387 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CH 3 -4-MeO-phenyl 388 cBu-CH(CH 3 ) 2-CH 3 -4-MeO-phenyl 389 l-cBu-CH(CH 2 CH 3 ) 2-CH 3 -4-MeO-phenyl 390 1-cBu-CH (CH 2 CH CH 3 ) 2-CH 3 -4-MeO-phenyl 391 l-cBu-CH(CH 2 OCH 3 ) 2 -CH3- 4 -MeO- phenyl 392 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2--CH 3 -4-MeO-phenyl 393 (cPr) 2 CH 2, 4-diCH 3 -phenyl 394 phenyl (cPr)CH 2, 4-diCH 3 -phenyl 395 2-furanyl (cPr)CH 2, 4-diCH 3 -phenyl 396 3-furan(cPr)CH 2, 4-diCH 3 -phenyl 397 2-thienyl(cPr)CH 2 , 4-diCH 3 -phenyl 398 3-thienyl(cPr)CH 2 , 4-diCH 3 -phenyl 399 2-isoxazolyl (cPr) CH 2 , 4-diCH 3 - henyl 400 2- (5-CH 3 -furanyl) (cPr) CH 2 , 4-diCH 3 -phenyl 401 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 , 4-diCH 3 -phenyl 402 cPr-CH(CH 3 ) 2 , 4-diCH 3 -phenyl 403 l-cPr-CH(CH 2 CH 3 ) 2 , 4-diCH 3 -phenyl 404 l-cPr-CH(CH 2 CH 2 CH 3 ) 2 , 4-diCH 3 -phenyl 405 l-cPr-CH(CH 2 OCH 3 ) 2 4-diCH 3 -phenyl 406 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2 4-diCH 3 -phenyl 407 (cBu) 2 CH 2 4-diCH 3 -phenyl 408 phenyl (cBu)CH 2 4-diCH 3 -phenyl 409 2-furanyl (cBu)CH 2 4-diCH 3 -phenyl 410 3-furan(cBu)CH 2 4-diCH 3 -phenyl 411 2-thienyl (cBu)CH 2 4-diCH 3 -phenyl 412 3-thienyl(cBu)CH 2 4-diCH 3 -phenyl 413 2-isoxazolyl (cBu) CH 2 , 4-diCH 3 -phenyl 414 2- (5-CH 3 -furanyl) (cBu)CH 2 , 4-diCH 3 -phenyl 415 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 , 4-diCH 3 -phenyl 416 cBu-CH(CH 3 ) 2 , 4-diCH 3 - henyl 417 l-cBu-CH(CH 2 CH 3 ) 2 , 4-diCH 3 -phenyl 418 l-cBu-CH(CH 2 CH 2 CH 3 ) 2 , 4-diCH 3 -phenyl 419 l-cBu-CH(CH 2 OCH 3 ) 2 , 4-diCH 3 -phenyl 420 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2 , 4-diCH 3 -phenyl 421 (cPr) 2 CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 422 phenyl (cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 423 2-furanyl (cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 424 3-furan(cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 425 2-thienyl(cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N- henyl 426 3-thienyl(cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 427 2-isoxazolyl (cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 428 2- (5-CH 3 -furanyl) (cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 429 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 -CH 3 -4- (CH 3 ) 2 N-phenyl 430 cPr-CH(CH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 431 l-cPr-CH(CH 2 CH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 432 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CH 3 -4- (CR " 3 ) 2 N-phenyl 433 l-cPr-CH(CH 2 OCH 3 ) 2-CH 3 -4- (CH 3 ) N-phenyl 434 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 435 (cBu) CH 2-CH 3 -4- (CH 3 ) 2 N-phenyl 436 phenyl (cBu)CH 2-CH 3 -4- (CH 3 ) N-phenyl 437 2-furanyl (cBu)CH 2-CH 3 -4- (CH 3 ) 2 N-phenyl 438 3-furan(cBu)CH 2-CH 3 -4- (CH 3 ) 2 N- henyl 439 2-thienyl(cBu)CH 2-CH 3 -4- (CH 3 ) 2 N-phenyl 440 3-thienyl(cBu)CH 2-CH 3 -4- (CH 3 ) 2 N-phenyl 441 2-isoxazolyl (cBu) CH 2-CH 3 -4- (CH 3 ) 2 N-phenyl 442 2- (5-CH 3 -furanyl) (cBu)CH 2-CH 3 -4- (CH 3 ) 2 N- henyl 443 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CH 3 -4- (CH 3 ) 2 N-phenyl 444 cBu-CH(CH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 445 l-cBu-CH(CH 2 CH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 446 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 447 l-cBu-CH(CH 2 OCH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 448 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2-CH 3 -4- (CH 3 ) 2 N-phenyl 449 (cPr) 2 CH 2-MeO-4- -CH 3 -phenyl 450 phenyl (cPr)CH 2-MeO-4- -CH 3 -phenyl 451 2-furanyl(cPr)CH 2-MeO-4- -CH 3 -phenyl 452 3-furan(cPr)CH 2-MeO-4- -CH 3 -phenyl 453 2-thienyl(cPr)CH 2-MeO-4- -CH 3 -phenyl 454 3-thienyl(cPr)CH 2-MeO-4- -CH -phenyl 455 2-isoxazolyl (cPr) CH 2-MeO-4- -CH 3 -phenyl 456 2- (5-CH 3 -furanyl) (cPr)CH 2-MeO-4- -CH 3 -phenyl 457 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-MeO-4- -CH 3 -phenyl 458 cPr-CH(CH 3 ) 2-MeO-4- -CH 3 -phenyl 459 l-cPr-CH(CH 2 CH 3 ) 2-MeO-4- -CH 3 -phenyl 460 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-MeO-4- -CH 3 -phenyl 461 l-cPr-CH(CH 2 OCH 3 ) 2-MeO-4- -CH 3 -phenyl 462 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-MeO-4- -CH 3 -phenyl 463 (cBu) 2 CH 2-MeO-4- -CH 3 -phenyl 464 phenyl (cBu)CH 2-MeO-4- -CH 3 -phenyl 465 2-furanyl (cBu)CH 2-MeO-4- -CH 3 -phenyl 466 3-furan(cBu)CH 2-MeO-4- -CH 3 -phenyl 467 2-thienyl(cBu)CH 2-MeO-4- -CH 3 -phenyl 468 3-thienyl(cBu)CH 2-MeO-4-CH 3 -phenyl 469 2-isoxazolyl (cBu) CH 2 -MeO- 4 -CH 3 -phenyl 470 2- (5-CH3- furanyl) (cBu)CH 2 -MeO- 4-CH3 -phenyl 471 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 -MeO- 4 -CH 3 -phenyl 472 cBu-CH(CH 3 ) 2 -MeO- 4 -CH 3 -phenyl 473 l-cBu-CH(CH 2 CH 3 ) 2 -MeO- 4 -CH 3 -phenyl 474 l-cBu-CH(CH 2 CH 2 CH 3 ) 2-MeO-4-CH 3 -phenyl 475 l-cBu-CH(CH OCH 3 ) 2 -MeO- 4 -CH 3 -phenyl 476 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2 -MeO- 4 -CH3 -phenyl 477 (cPr) 2 CH 2 -MeO- 4-CF3 -phenyl 478 phenyl (cPr)CH 2-MeO-4-CF 3 -phenyl 479 2- f uranyl (cPr)CH 2-MeO-4-CF3-phenyl 480 3-furan(cPr)CH 2-MeO-4-CF 3 -phenyl 481 2-thienyl(cPr)CH 2-MeO-4-CF 3 -phenyl 482 3-thienyl(cPr)CH 2-MeO-4-CF 3 -phenyl 483 2-isoxazolyl (cPr) CH 2-MeO-4-CF 3 -phenyl 484 2 - ( 5 -CH 3 - furanyl ) ( cPr ) CH 2 -MeO- 4 -CF 3 -phenyl 485 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 -MeO- 4-CF3 -phenyl 486 cPr-CH(CH 3 ) 2-MeO-4-CF 3 -phenyl 487 l-cPr-CH(CH 2 CH 3 ) 2-MeO-4-CF 3 -phenyl 488 1-cPr-CH (CH 2 CH 2 CH 3 ) 2 -MeO- 4-CF3 -phenyl 489 l-cPr-CH(CH 2 OCH 3 ) 2-MeO-4-CF 3 -phenyl 490 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-MeO-4-CF3-phenyl 491 (cBu) 2 CH 2-MeO-4-CF3-phenyl 492 phenyl (cBu)CH 2-MeO-4-CF 3 -phenyl 493 2- furanyl (cBu)CH 2 -MeO- 4-CF3 -phenyl 494 3-furan(cBu)CH 2-MeO-4-CF 3 -phenyl 495 2 - thienyl (cBu)CH 2 -MeO- 4-CF3 -phenyl 496 3-thienyl(cBu)CH 2-MeO-4-CF3-phenyl 497 2-isoxazolyl (cBu) CH 2 -MeO- 4 -CF 3 -phenyl 498 2- (5-CH 3 -furanyl) (cBu)CH 2 -MeO- 4 -CF 3 -phenyl 499 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 -MeO- 4 -CF 3 -phenyl 500 cBu-CH(CH 3 ) 2-MeO-4-CF 3 -phenyl 501 l-cBu-CH(CH CH 3 ) 2-MeO-4-CF 3 -phenyl 502 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-MeO-4-CF 3 -phenyl 503 l-cBu-CH(CH 2 OCH 3 ) 2-MeO-4-CF 3 -phenyl 504 1-cBu-CH (CH CH 2 OCH 3 ) 2 -MeO- 4 -CF 3 -phenyl 505 (cPr) 2 CH 2 - MeO- 4 - C 1 - henyl 506 phenyl (cPr)CH 2-MeO-4-Cl-phenyl 507 2-furanyl (cPr) CH 2-MeO-4-Cl-phenyl 508 3-furan(cPr)CH 2-MeO-4-Cl-phenyl 509 2-thienyl(cPr)CH 2-MeO-4-Cl-phenyl 510 3-thienyl(cPr)CH 2-MeO-4-C1-phenyl 511 2-isoxazolyl (cPr) CH 2-MeO-4-Cl-phenyl 512 2- (5-CH 3 -furanyl) (cPr)CH 2-MeO-4-Cl-phenyl 513 2- (4-CH 3 -isoxazolyl) (cPr)CH 2-MeO-4-Cl-phenyl 514 cPr-CH(CH 3 ) 2-MeO-4-Cl-phenyl 515 l-cPr-CH(CH 2 CH 3 ) 2-MeO-4-Cl-phenyl 516 1-cPr-CH (CH 2 CHCH 3 ) 2-MeO-4-Cl-phenyl 517 l-cPr-CH(CH 2 OCH 3 ) 2-MeO-4-Cl-phenyl 518 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2-MeO-4-Cl-phenyl 519 (cBu) 2 CH 2-MeO-4-Cl-phenyl 520 phenyl (cBu)CH 2-MeO-4-Cl-phenyl 521 2-furanyl (cBu)CH 2-MeO-4-Cl-phenyl 522 3-furan(cBu)CH 2-MeO-4-Cl-phenyl 523 2-thienyl(cBu)CH 2-MeO-4-Cl-phenyl 524 3-thienyl(cBu)CH 2-MeO-4-Cl-phenyl 525 2-isoxazolyl (cBu) CH 2-MeO-4-Cl-phenyl 526 2- (5-CH 3 -furanyl) (cBu)CH 2-MeO-4-Cl-phenyl 527 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-MeO-4-Cl-phenyl 528 cBu-CH(CH 3 ) 2-MeO-4-Cl-phenyl 529 l-cBu-CH(CH 2 CH 3 ) 2-MeO-4-Cl-phenyl 530 l-cBu-CH(CH 2 CH 2 CH 3 ) 2-MeO-4-Cl-phenyl 531 l-cBu-CH(CH 2 OCH 3 ) 2-MeO-4-Cl-phenyl 532 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2-MeO-4-Cl-phenyl 533 (cPr) 2 CH 2 , 4-diMeO-phenyl 534 phenyl (cPr)CH 2 , 4-diMeO-phenyl 535 2-furanyl (cPr)CH 2 , 4-diMeO- henyl 536 3-furan(cPr)CH 2 , 4-diMeO-phenyl 537 2-thienyl(cPr)CH 2 , 4-diMeO-phenyl 538 3-thienyl(cPr)CH 2 , 4-diMeO- henyl 539 2-isoxazolyl (cPr) CH 2 , 4-diMeO-phenyl 540 2- (5-CH 3 -furanyl) (cPr)CH 2 , 4-diMeO-phenyl 541 2- (4-CH 3 -isoxazolyl) (cPr)CH 2 , 4-diMeO-phenyl 542 cPr-CH(CH 3 ) 2 , 4-diMeO-phenyl 543 l-cPr-CH(CH 2 CH 3 ) 2 , 4-diMeO-phenyl 544 l-cPr-CH(CH 2 CH 2 CH 3 ) 2,, 4-diMeO-phenyl 545 l-cPr-CH(CH 2 OCH 3 ) 2,, 4-diMeO-phenyl 546 l-cPr-CH(CH 2 CHOCH 3 ) 2,, 4-diMeO-phenyl 547 (cBu) 2 CH 2,, 4-diMeO-phenyl 548 phenyl (cBu)CH 2,, 4-diMeO-phenyl 549 2-furanyl (cBu)CH 2,, 4-diMeO-phenyl 550 3-furan(cBu)CH 2,, 4-diMeO-phenyl 551 2-thienyl(cBu)CH 2,, 4-diMeO-phenyl 552 3-thienyl(cBu)CH 2,, 4-diMeO-phenyl 553 2-isoxazolyl (cBu) CH 2,, 4-diMeO-phenyl 554 2- (5-CH 3 -furanyl) (cBu)CH 2,, 4-diMeO-phenyl 555 2- (4-CH 3 -isoxazolyl) (cBu)CH 2,, 4-diMeO-phenyl 556 cBu-CH(CH 3 ) 2,, 4-diMeO-phenyl 557 l-cBu-CH(CH 2 CH 3 ) 2,, 4-diMeO-phenyl 558 1-cBu-CH (CH 2 CH 2 CH 3 ) 2,, 4-diMeO-phenyl 559 l-cBu-CH(CH 2 OCH 3 ) 2,, 4-diMeO-phenyl 560 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2,, 4-diMeO-phenyl 561 (cPr) 2 CH 2,, 4-diCl-6-CH 3 -phenyl 562 phenyl (cPr)CH 2,, 4-diCl-6-CH 3 -phenyl 563 2-furanyl(cPr)CH 2,, 4-diCl-6-CH 3 -phenyl 564 3-furan(cPr)CH 2,, 4-diCl-6-CH 3 -phenyl 565 2-thienyl(cPr)CH 2,, 4-diCl-6-CH 3 -phenyl 566 3-thienyl(cPr)CH 2,, 4-diCl-6-CH 3 -phenyl 567 2-isoxazolyl (cPr) CH 2,, 4-diCl-6-CH 3 -phenyl 568 2- (5-CH 3 -1uranyl) (cPr)CH 2,, 4-diCl-6-CH 3 -phenyl 569 2-(4-CH 3 -isoxazolyl) (cPr)CH 2,, 4-diCl-6-CH 3 -phenyl 570 cPr-CH(CH 3 ) 2,, 4-diCl-6-CH 3 -phenyl 571 l-cPr-CH(CH 2 CH 3 ) 2,, 4-diCl-6-CH 3 -phenyl 572 1-cPr-CH (CH 2 CH 2 CH 3 ) 2,, 4-diCl-6-CH 3 -phenyl 573 l-cPr-CH(CH 2 OCH 3 ) 2,, 4-diCl-6-CH 3 -phenyl 574 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2,, 4-diCl-6-CH 3 -phenyl 575 (cBu) 2 CH 2,, 4-diCl-6-CH 3 -phenyl 576 phenyl (cBu)CH 2,, 4-diCl-6-CH 3 -phenyl 577 2-furanyl (cBu)CH 2,, 4-diCl-6-CH 3 -phenyl 578 3-furan(cBu)CH 2,, 4-diCl-6-CH 3 -phenyl 579 2-thienyl(cBu)CH 2,, 4-diCl-6-CH 3 -phenyl 580 3-thienyl(cBu)CH 2,, 4-diCl-6-CH 3 -phenyl 581 2-isoxazolyl (cBu) CH 2,, 4-diCl-6-CH 3 -phenyl 582 2- (5-CH 3 -furanyl) (cBu)CH 2 , 4-diCl-6-CH 3 -phenyl 583 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 , 4-diCl-6-CH 3 -phenyl 584 cBu-CH(CH 3 ) 2 , 4-diCl-6-CH 3 -phenyl 585 l-cBu-CH(CH 2 CH 3 ) 2 4-diCl-6-CH 3 -phenyl 586 1-cBu-CH (CH 2 CH 2 CH 3 ) 2 , 4-diCl-6-CH 3 -phenyl 587 l-cBu-CH(CH 2 OCH 3 ) 2 , 4-diCl-6-CH 3 -phenyl 588 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2 4-diCl-6-CH 3 -phenyl 589 (cPr) 2 CH 2, 4-diCl-5-F-phenyl 590 phenyl (cPr)CH 2 , 4-diCl-5-F-phenyl 591 2-furanyl (cPr)CH 2 4-diCl-5-F-phenyl 592 3-furan(cPr)CH 2 , 4-diCl-5-F-phenyl 593 2-thienyl(cPr)CH 2 , 4-diCl-5-F-phenyl 594 3-thienyl(cPr)CH 2 4-diCl-5-F-phenyl 595 2-isoxazolyl (cPr) CH 2 , 4-diCl-5-F-phenyl 596 2- (5-CH 3 -furanyl) (cPr)CH 2 4-diCl-5-F-phenyl 597 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 4-diCl-5-F-phenyl 598 cPr-CH(CH 3 ) 2 4-diCl-5-F-phenyl 599 l-cPr-CH(CH 2 CH 3 ) 2 4-diCl-5-F-phenyl 600 1-cPr-CH (CH 2 CH 2 CH 3 ) 2 4-diCl-5-F-phenyl 601 l-cPr-CH(CH 2 OCH 3 ) 2 4-diCl-5-F-phenyl 602 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2 4-diCl-5-F-phenyl 603 (cBu) 2 CH 2 4-diCl-5-F-phenyl 604 phenyl (cBu)CH 2 4-diCl-5-F-phenyl 605 2-furanyl (cBu)CH 2 4-diCl-5-F-phenyl 606 3-furan(cBu)CH 2 4-diCl-5-F-phenyl 607 2-thienyl(cBu)CH 2 4-diCl-5-F-phenyl 608 3-thienyl(cBu)CH 2 , 4-diCl-5-F-phenyl 609 2-isoxazolyl (cBu)CH 2 4-diCl-5-F-phenyl 610 2- (5-CH 3 -furanyl) (cBu)CH 2 4-diCl-5-F-phenyl 611 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 , 4-diCl-5-F-phenyl 612 cBu-CH(CH 3 ) 2 4-diCl-5-F-phenyl 613 l-cBu-CH(CH 2 CH 3 ) 2 4-diCl-5-F-phenyl 614 1-cBu-CH (CH 2 CH 2 CH 3 ) 2 , 4-diCl-5-F-phenyl 615 l-cBu-CH(CH 2 OCH 3 ) 2 4-diCl-5-F-phenyl 616 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2 4-diCl-5-F-phenyl 617 (cPr) 2 CH 2 4-diCl-6-MeS-phenyl 618 phenyl (cPr)CH 2 4-diCl-6-MeS-phenyl 619 2-furanyl (cPr)CH 2 4-diCl-6-MeS-phenyl 620 3-furan(cPr)CH 2, 4-diCl-6-MeS-phenyl 621 2 -thienyl (cPr)CH 2, 4-diCl-6-MeS-phenyl 622 3-thienyl(cPr)CH 2, 4-diCl-6-MeS-phenyl 623 2-isoxazolyl (cPr) CH 2, 4-diCl-6-MeS-phenyl 624 2- (5-CH 3 -f uranyl) (cPr)CH 2, 4-diCl-6-MeS-phenyl 625 2-(4-CH 3 -isoxazolyl) (cPr)CH 2, 4-diCl-6-MeS-phenyl 626 cPr-CH(CH 3 ) 2, 4-diCl-6-MeS-phenyl 627 l-cPr-CH(CH 2 CH 3 ) 2, 4-diCl-6-MeS-phenyl 628 l-cPr-CH(CH 2 CH 2 CH 3 ) 2, 4-diCl-6-MeS-phenyl 629 l-cPr-CH(CH 2 OCH 3 ) 2, 4-diCl-6-MeS-phenyl 630 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2, 4-diCl-6-MeS-phenyl 631 (cBu) 2 CH 2, 4-diCl-6-MeS-phenyl 632 phenyl (cBu)CH 2, 4-diCl-6-MeS-phenyl 633 2- furanyl (cBu)CH 2 4-diCl-6-MeS-phenyl 634 3-furan(cBu)CH 2 4-diCl-6-MeS-phenyl 635 2-thienyl(cBu)CH 2 4-diCl-6-MeS-phenyl 636 3-thienyl(cBu)CH 2 4-diCl-6-MeS-phenyl 637 2-isoxazolyl (cBu) CH 2 4-diCl-6-MeS-phenyl 638 2- (5-CH 3 - furanyl) (cBu)CH 2 , 4-diCl-6-MeS-phenyl 639 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 , 4-diCl-6-MeS-phenyl 640 cBu-CH(CH 3 ) 2 , 4-diCl-6-MeS-phenyl 641 l-cBu-CH(CH 2 CH 3 ) 2 , 4-diCl-6-MeS-phenyl 642 1-cBu-CH (CH 2 CH 2 CH 3 ) 2 , 4-diCl-6-MeS-phenyl 643 l-cBu-CH(CH 2 OCH 3 ) 2 , 4-diCl-6-MeS-phenyl 644 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2 , 4-diCl-6-MeS-phenyl 645 (cPr) 2 CH 2 , 4-diCl-6-MeO-phenyl 646 phenyl (cPr)CH 2 , 4-diCl-6-MeO-phenyl 647 2- f uranyl (cPr)CH 2 , 4-diCl-6-MeO-phenyl 648 3-furan(cPr)CH 2 , 4-diCl-6-MeO-phenyl 649 2-thienyl(cPr)CH 2 , 4-diCl-6-MeO-phenyl 650 3-thienyl(cPr)CH 2 , 4-diCl-6-MeO-phenyl 651 2-isoxazolyl (cPr) CH 2 , 4-diCl-6-MeO-phenyl 652 2- (5-CH 3 -furanyl) (cPr)CH 2 , 4-diCl-6-MeO-phenyl 653 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 , 4-diCl-6-MeO-phenyl 654 cPr-CH(CH 3 ) 2 , 4-diCl-6-MeO-phenyl 655 l-cPr-CH(CH 2 CH 3 ) 2 , 4-diCl-6-MeO-phenyl 656 1-cPr-CH (CH 2 CH 2 CH 3 ) 2 , 4-diCl-6-MeO-phenyl 657 l-cPr-CH(CH 2 OCH 3 ) 2 , 4-diCl-6-MeO-phenyl 658 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2, 4-diCl-6-MeO-phenyl 659 (cBu) 2 CH 2 , 4-diCl-6-MeO-phenyl 660 phenyl ( cBu )CH 2, 4-diCl-6-MeO-phenyl 661 2- furanyl (cBu)CH 2, 4-diCl-6-MeO-phenyl 662 3-furan(cBu)CH 2 , 4-diCl-6-MeO-phenyl 663 2-thienyl(cBu)CH 2, 4-diCl-6-MeO-phenyl 664 3 - thienyl (cBu)CH 2, 4-diCl-6-MeO-phenyl 665 2-isoxazolyl (cBu) CH 2 , 4-diCl-6-MeO-phenyl 666 2- (5-CH3- furanyl) (cBu)CH 2, 4-diCl-6-MeO-phenyl 667 2-(4-CH 3 -isoxazolyl) (cBu)CH 2, 4-diCl-6-MeO-phenyl 668 cBu-CH(CH 3 ) 2 , 4-diCl-6-MeO-phenyl 669 l-cBu-CH(CH 2 CH 3 ) 2, 4-diCl-6-MeO-phenyl 670 1-cBu-CH (CH 2 CH CH 3 ) 2 , 4-diCl-6-MeO-phenyl 671 l-cBu-CH(CH 2 OCH 3 ) 2 , 4-diCl-6-MeO-phenyl 672 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2 , 4-diCl-6-MeO-phenyl 673 (cPr) 2 CH 2 , 5-diCl-4-MeO-phenyl 674 phenyl (cPr)CH 2 , 5-diCl-4-MeO-phenyl 675 2- f uranyl (cPr)CH 2, 5-diCl-4-MeO-phenyl 676 3-furan(cPr)CH 2 , 5-diCl-4-MeO-phenyl 677 2-thienyl(cPr)CH 2 , 5-diCl-4-MeO-phenyl 678 3-thienyl(cPr)CH 2 , 5-diCl-4-MeO-phenyl 679 2-isoxazolyl (cPr) CH 2 , 5-diCl-4-MeO-phenyl 680 2- (5-CH3- furanyl) (cPr)CH 2, 5-diCl-4-MeO-phenyl 681 2-(4-CH 3 -isoxazolyl) (cPr)CH 2, 5-diCl-4-MeO-phenyl 682 cPr-CH(CH 3 ) 2 , 5-diCl-4-MeO-phenyl 683 l-cPr-CH(CH 2 CH 3 ) 2 , 5-diCl-4-MeO-phenyl 684 1-cPr-CH (CH 2 CH 2 CH 3 ) 2 , 5-diCl-4-MeO-phenyl 685 l-cPr-CH(CH 2 OCH 3 ) 2 , 5-diCl-4-MeO-phenyl 686 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2 , 5-diCl-4-MeO-phenyl 687 (cBu) 2 CH 2, 5-diCl-4-MeO-phenyl 688 phenyl (cBu)CH 2, 5-diCl-4-MeO-phenyl 689 2- furanyl (cBu)CH 2 , 5-diCl-4-MeO-phenyl 690 3-furan(cBu)CH 2 , 5-diCl-4-MeO-phenyl 691 2 -thienyl (cBu)CH 2 , 5-diCl-4-MeO-phenyl 692 3 -thienyl (cBu)CH 2 , 5-diCl-4-MeO-phenyl 693 2-isoxazolyl (cBu) CH 2 , 5-diCl-4-MeO-phenyl 694 2- (5-CH3- furanyl) (cBu)CH 2 , 5-diCl-4-MeO-phenyl 695 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 , 5-diCl-4-MeO-phenyl 696 cBu-CH(CH 3 ) 2 , 5-diCl-4-MeO-phenyl 697 l-cBu-CH(CH 2 CH 3 ) 2, 5-diCl-4-MeO-phenyl 698 1-cBu-CH (CH 2 CH 2 CH 3 ) 2, 5-diCl-4-MeO-phenyl 699 l-cBu-CH(CH 2 OCH 3 ) 2 , 5-diCl-4-MeO-phenyl 700 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2 , 5-diCl-4-MeO-phenyl 701 (cPr) 2 CH 2,4,6-triCl-phenyl 702 phenyl (cPr)CH 2,4,6-triCl-phenyl 703 2-furanyl(cPr)CH 2,4, 6-triCl-phenyl 704 3-furan(cPr)CH 2,4, 6-triCl-phenyl 705 2-thienyl(cPr)CH 2,4, 6-triCl-phenyl 706 3-thienyl(cPr)CH 2,4,6-triCl-phenyl 707 2-isoxazolyl (cPr) CH 2,4, 6-triCl-phenyl 708 2- (5-CH 3 -furanyl) (cPr)CH 2,4,6-triCl-phenyl 709 2- (4-CH 3 -isoxazolyl) (cPr)CH 2,4, 6-triCl-phenyl 710 cPr-CH(CH 3 ) 2,4, 6-triCl-phenyl 711 l-cPr-CH(CH 2 CH 3 ) 2,4, 6-triCl-phenyl 712 1-cPr-CH (CH 2 CH 2 CH 3 ) 2,4, 6-triCl-phenyl 713 l-cPr-CH(CH 2 OCH 3 ) 2,4,6-triCl-phenyl 714 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2,4, 6-triCl-phenyl 715 (cBu) CH 2,4, 6-triCl-phenyl 716 phenyl (cBu)CH 2,4,6-triCl-phenyl 717 2-furanyl (cBu)CH 2,4, 6-triCl-phenyl 718 3-furan(cBu)CH 2,4,6-triCl-phenyl 719 2-thienyl(cBu)CH 2,4,6-triCl-phenyl 720 3-thienyl(cBu)CH 2,4, 6-triCl-phenyl 721 2-isoxazolyl (cBu) CH 2,4,6-triCl-phenyl 722 2- (5-CH 3 -furanyl) (cBu)CH 2,4, 6-triCl-phenyl 723 2-(4-CH 3 -isoxazolyl) (cBu)CH 2,4,6-triCl-phenyl 724 cBu-CH(CH 3 ) 2,4, 6-triCl-phenyl 725 l-cBu-CH(CH 2 CH 3 ) 2,4,6-triCl-phenyl 726 1-cBu-CH (CHCH 2 CH 3 ) 2 , 4, 6-triCl-phenyl 727 l-cBu-CH(CH 2 OCH 3 ) 2,4,6-triCl-phenyl 728 l-cBu-CH(CHCH 2 OCH 3 ) 2,4,6-triCl-phenyl 729 (cPr) 2 CH 2-Cl-4-CH 3 -5-F-phenyl 730 phenyl (cPr)CH 2-Cl-4-CH 3 -5-F-phenyl 731 2-furanyl (cPr)CH 2-Cl-4-CH 3 -5-F-phenyl 732 3-furan(cPr)CH 2-Cl-4-CH 3 -5-F-phenyl 733 2-thienyl(cPr)CH 2-Cl-4-CH 3 -5-F-phenyl 734 3-thienyl(cPr)CH 2-Cl-4-CH 3 -5-F-phenyl 735 2-isoxazolyl (cPr) CH 2-Cl-4-CH 3 -5-F-phenyl 736 2- (5-CH 3 -furanyl) (cPr)CH 2-Cl-4-CH 3 -5-F-phenyl 737 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-Cl-4-CH 3 -5-F-phenyl 738 cPr-CH(CH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 739 l-cPr-CH(CH 2 CH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 740 l-cPr-CH(CH 2 CH 2 CH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 741 l-cPr-CH(CH 2 OCH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 742 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 743 (cBu) 2 CH 2-Cl-4-CH 3 -5-F-phenyl 744 phenyl (cBu)CH 2-Cl-4-CH 3 -5-F-phenyl 745 2- furanyl (cBu)CH 2-Cl-4-CH 3 -5-F-phenyl 746 3-furan(cBu)CH 2-Cl-4-CH 3 -5-F-phenyl 747 2 - thienyl (cBu)CH 2-Cl-4-CH 3 -5-F-phenyl 748 3-thienyl(cBu)CH 2-Cl-4-CH 3 -5-F-phenyl 749 2-isoxazolyl (cBu) CH 2-Cl-4-CH 3 -5-F-phenyl 750 2- (5-CH3 -furanyl) (cBu)CH 2-Cl-4-CH 3 -5-F-phenyl 751 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-Cl-4-CH 3 -5-F-phenyl 752 cBu-CH(CH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 753 l-cBu-CH(CH 2 CH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 754 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 755 l-cBu-CH(CH 2 OCH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 756 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2-Cl-4-CH 3 -5-F-phenyl 757 (cPr) 2 CH 2-Cl-4-MeO-5-CH 3 -phenyl 758 phenyl (cPr)CH 2-Cl-4-MeO-5-CH 3 -phenyl 759 2- f uranyl (cPr)CH 2-Cl-4-MeO-5-CH 3 -phenyl 760 3-furan(cPr)CH 2-Cl-4-MeO-5-CH 3 -phenyl 761 2-thienyl(cPr)CH 2-Cl-4-MeO-5-CH 3 -phenyl 762 3-thienyl(cPr)CH 2-Cl-4-MeO-5-CH 3 -phenyl 763 2-isoxazolyl (cPr) CH 2-Cl-4-MeO-5-CH 3 -phenyl 764 2- (5-CH3- furanyl) (cPr)CH 2-Cl-4-MeO-5-CH 3 -phenyl 765 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-Cl-4-MeO-5-CH 3 -phenyl 766 cPr-CH(CH 3 ) 2-Cl-4-MeO-5-CH 3 -phenyl 767 l-cPr-CH(CH 2 CH 3 ) 2-Cl-4-MeO-5-CH 3 -phenyl 768 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-MeO-5-CH 3 -phenyl 769 l-cPr-CH(CH 2 OCH 3 ) 2-Cl-4-MeO-5-CH 3 -phenyl 770 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2 -Cl-4-MeO-5-CH 3 -phenyl 771 (cBu) 2 CH 2-Cl-4-MeO-5-CH 3 -phenyl 772 phenyl (cBu)CH 2-Cl-4-MeO-5- CH 3 -phenyl 773 2-furanyl (cBu)CH 2-Cl-4-MeO-5- CH 3 -phenyl 774 3-furan(cBu)CH 2-Cl-4-MeO-5- CH 3 -phenyl 775 2-thienyl (cBu)CH 2-Cl-4-MeO-5- CH 3 -phenyl 776 3-thienyl (cBu)CH 2-Cl-4-MeO-5- CH 3 -phenyl 777 2-isoxazolyl (cBu)CH 2-Cl-4-MeO-5- CH 3 -phenyl 778 2- (5-CH 3 -furanyl) (cBu)CH 2-Cl-4-MeO-5- ■ CH 3 -phenyl 779 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-C1-4-MSO-5- ■ CH -phenyl 780 cBu-CH(CH 3 ) 2-Cl-4-MeO-5- ■ CH 3 -phenyl 781 l-cBu-CH(CH 2 CH 3 ) 2-Cl-4-MeO-5- ■ CH 3 -phenyl 782 l-cBu-CH(CH 2 CH 2 CH 3 ) 2-Cl-4-MeO-5- ■ CH 3 -phenyl 783 l-cBu-CH(CH 2 OCH 3 ) 2-Cl-4-MeO-5- ■ CH 3 -phenyl 784 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2-Cl-4-MeO-5- • CH 3 -phenyl 785 (cPr) 2 CH 2-Cl-4-MeO-5- ■ F- phenyl 786 phenyl (cPr)CH 2-Cl-4-MeO-5- ■ F-phenyl 787 2-furanyl (cPr)CH 2-Cl-4-MeO-5- F-phenyl 788 3-furan(cPr)CH 2-Cl-4-MeO-5- ■ F-phenyl 789 2-thienyl(cPr)CH 2-Cl-4-MeO-5- ■ F-phenyl 790 3-thienyl(cPr)CH 2-Cl-4-MeO-5- ■ F-phenyl 791 2-isoxazolyl (cPr)CH 2-Cl-4-MeO-5- ■ F-phenyl 792 2- (5-CH 3 -furanyl) (cPr)CH 2-Cl-4-MeO-5- • F-phenyl 793 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-Cl-4-MeO-5- ■ F-phenyl 794 cPr-CH(CH 3 ) 2-Cl-4-MeO-5- ■ F-phenyl 795 l-cPr-CH(CH 2 CH 3 ) 2-Cl-4-MeO-5- ■ F-phenyl 796 l-cPr-CH(CH 2 CH 2 CH 3 ) 2-Cl-4-MeO-5- -F-phenyl 797 l-cPr-CH(CH 2 OCH 3 ) 2-Cl-4-MeO-5- -F-phenyl 798 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2-Cl-4-MeO-5- -F-phenyl 799 (cBu) 2 CH 2-Cl-4-MeO-5- -F-phenyl 800 phenyl (cBu)CH 2-Cl-4-MeO-5- -F-phenyl 801 2-furanyl(cBu)CH 2-Cl-4-MeO-5- -F-phenyl 802 3-furan(cBu)CH 2-Cl-4-MeO-5- -F-phenyl 803 2-thienyl(cBu)CH 2-Cl-4-MeO-5- -F-phenyl 804 3-thienyl(cBu)CH 2-Cl-4-MeO-5- -F-phenyl 805 2-isoxazolyl (cBu)CH 2-Cl-4-MeO-5- -F-phenyl 806 2- (5-CH 3 -furanyl ) (cBu)CH 2-Cl-4-MeO-5- -F-phenyl 807 2 - (4-CH 3 - isoxazolyl ) (cBu) CH 2-Cl-4-MeO-5- -F-phenyl 808 cBu-CH (CH 3 ) 2-Cl-4-MeO-5- -F-phenyl 809 l-cBu-CH (CH 2 CH 3 ) 2-Cl-4-MeO-5- -F-phenyl 810 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-Cl-4-MeO-5-F-phenyl 811 l-cBu-CH(CH 2 OCH 3 ) 2-Cl-4-MeO-5-F-phenyl 812 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2-Cl-4-MeO-5-F-phenyl 813 (cPr) 2 CH 2-CH 3 -4-MeO-5-Cl-phenyl 814 phenyl (cPr)CH 2 -CH 3 -4-MeO-5-Cl-phenyl 815 2-furanyl (cPr)CH 2 -CH 3 -4-MeO-5-Cl-phenyl 816 3-furan(cPr)CH 2-CH 3 -4-MeO-5-Cl-phenyl 817 2-thienyl(cPr)CH 2-CH 3 -4-MeO-5-Cl-phenyl 818 3-thienyl(cPr)CH 2-CH 3 -4-MeO-5-Cl-phenyl 819 2-isoxazolyl (cPr) CH 2-CH 3 -4-MeO-5-Cl-phenyl 820 2- (5-CH 3 -furanyl) (cPr)CH 2 -CH 3 -4-MeO-5-Cl-phenyl 821 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-CH 3 -4-MeO-5-Cl-phenyl 822 cPr-CH(CH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 823 l-cPr-CH(CH 2 CH 3 ) 2-CH 3 -4-MeO-5-Cl-phenyl 824 l-cPr-CH(CH 2 CH 2 CH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 825 l-cPr-CH(CH 2 OCH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 826 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 827 (cBu) 2 CH 2-CH 3 -4-MeO-5-Cl-phenyl 828 phenyl (cBu)CH 2 -CH 3 -4-MeO-5-Cl-phenyl 829 2-furanyl (cBu)CH 2-CH 3 -4-MeO-5-Cl-phenyl 830 3-furan(cBu)CH 2 -CH 3 -4-MeO-5-Cl-phenyl 831 2-thienyl(cBu)CH 2-CH 3 -4-MeO-5-Cl-phenyl 832 3-thienyl(cBu)CH 2 -CH 3 -4-MeO-5-Cl-phenyl 833 2-isoxazolyl (cBu) CH 2 -CH 3 -4-MeO-5-Cl-phenyl 834 2- (5-CH 3 -furanyl) (cBu)CH 2 -CH 3 -4-MeO-5-Cl-phenyl 835 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CH 3 -4-MeO-5-Cl-phenyl 836 cBu-CH(CH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 837 l-cBu-CH(CH 2 CH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 838 l-cBu-CH(CH 2 CH 2 CH 3 ) 2-CH 3 -4-MeO-5-Cl-phenyl 839 l-cBu-CH(CH 2 OCH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 840 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2 -CH 3 -4-MeO-5-Cl-phenyl 841 (cPr) 2 CH 2 , 5-diCH 3 -4-MeO-phenyl 842 phenyl (cPr)CH 2 , 5-diCH 3 -4-MeO-phenyl 843 2-furanyl (cPr)CH 2 , 5-diCH 3 -4-MeO-phenyl 844 3-furan(cPr)CH 2 , 5-diCH 3 -4-MeO-phenyl 845 2-thienyl(cPr)CH 2 , 5-diCH 3 -4-MeO-phenyl 846 3-thienyl(cPr)CH 2 , 5-diCH 3 -4-MeO-phenyl 847 2-isoxazolyl (cPr) CH 2 , 5-diCH 3 -4-MeO-phenyl 848 2- (5-CH 3 - furanyl) (cPr)CH 2 , 5-diCH 3 -4-MeO-phenyl 849 2-(4-CH 3 -isoxazolyl) (cPr)CH 2 , 5-diCH 3 -4-MeO-phenyl 850 cPr-CH(CH 3 ) 2 , 5-diCH 3 -4-MeO-phenyl 851 l-cPr-CH(CH 2 CH 3 ) 2 , 5-diCH3-4-MeO-phenyl 852 l-cPr-CH(CH 2 CH 2 CH 3 ) 2 , 5-diCH 3 -4-MeO-phenyl 853 l-cPr-CH(CH OCH 3 ) 2 , 5-diCH3-4-MeO-phenyl 854 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2 , 5-diCH3-4-MeO-phenyl 855 (cBu) 2 CH 2 , 5-diCH 3 -4-MeO-phenyl 856 phenyl (cBu)CH 2 , 5-diCH 3 -4-MeO-phenyl 857 2 - furanyl ( cBu) CH 2 , 5-diCH 3 -4-MeO-phenyl 858 3-furan(cBu)CH 2 , 5-diCH 3 -4-MeO-phenyl 859 2-thienyl(cBu)CH 2 , 5-diCH 3 -4-MeO-phenyl 860 3-thienyl(cBu)CH 2 , 5-diCH3-4-MeO-phenyl 861 2-isoxazolyl (cBu) CH 2 , 5-diCH 3 -4-MeO-phenyl 862 2- (5-CH3- furanyl) (cBu)CH 2 , 5-diCH3-4-MeO-phenyl 863 2-(4-CH 3 -isoxazolyl) (cBu)CH 2 , 5-diCH 3 -4-MeO-phenyl 864 cBu-CH(CH 3 ) 2 , 5-diCH3-4-MeO-phenyl 865 l-cBu-CH(CH 2 CH 3 ) 2 , 5-diCH 3 -4-MeO-phenyl 866 1-cBu-CH (CH 2 CH 2 CH 3 ) 2 , 5-diCH 3 -4-MeO-phenyl 867 l-cBu-CH(CH 2 OCH 3 ) 2 , 5-diCH 3 -4-MeO-phenyl 868 1-cBu-CH (CH CH 2 OCH 3 ) 2 , 5-diCH 3 -4-MeO-phenyl 869 (cPr) 2 CH 2 -CH3-4-MeO-5 -F-phenyl 870 phenyl (cPr)CH 2 -CH3-4-MeO-5 -F-phenyl 871 2-furanyl(cPr)CH 2-CH3-4-MeO-5-F-phenyl 872 3-furan(cPr)CH 2-CH3-4-MeO-5-F-phenyl 873 2-thienyl(cPr)CH 2-CH3-4-MeO-5-F-phenyl 874 3-thienyl(cPr)CH 2-CH3-4-MeO-5-F-phenyl 875 2-isoxazolyl (cPr) CH 2 -CH3-4-MeO-5 -F-phenyl 876 2- (5-CH3- furanyl) (cPr)CH 2-CH3-4-MeO-5-F-phenyl 877 2- (4-CH3- isoxazolyl) (cPr)CH 2-CH3-4-MeO-5-F-phenyl 878 cPr-CH(CH 3 ) 2 -CH3-4-MeO-5 -F-phenyl 879 l-cPr-CH(CH 2 CH 3 ) 2 -CH3-4-MeO-5 -F-phenyl 880 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CH3-4-MeO-5-F-phenyl 881 l-cPr-CH(CH 2 OCH 3 ) 2-CH3-4-MeO-5-F-phenyl 882 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-CH3-4-MeO-5-F-phenyl 883 (cBu) 2 CH 2-CH3-4-MeO-5-F-phenyl 884 phenyl (cBu)CH 2-CH3-4-MeO-5-F-phenyl 885 2-furanyl(cBu)CH 2-CH3-4-MeO-5-F-phenyl 886 3-furan(cBu)CH 2-CH 3 -■4-MeO-5-F-phenyl 887 2-thienyl(cBu)CH 2-CH 3 -•4-MeO-5-F-phenyl 888 3-thienyl(cBu)CH 2-CH 3 - ■ 4-MeO-5-F-phenyl 889 2-isoxazolyl (cBu) CH 2-CH 3 - ■ 4-MeO-5-F-phenyl 890 2- (5-CH 3 - furanyl) (cBu)CH 2-CH 3 - ■ 4-MeO-5-F-phenyl 891 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CH 3 --4-MeO-5-F-phenyl 892 cBu-CH(CH 3 ) 2-CH3 -4-MeO-5-F-phenyl 893 l-cBu-CH(CH 2 CH 3 ) 2-CH 3 -•4-MeO-5-F-phenyl 894 1-cBu-CH (CH 2 CH 2 CH 3 ) 2-CH3 -4-MeO-5-F-phenyl 895 l-cBu-CH(CH 2 OCH 3 ) 2-CH 3 .-4-MeO-5-F-phenyl 896 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2-CH3 -4-MeO-5-F-phenyl 897 (cPr) 2 CH 2,4,6 -triCH3-phenyl 898 phenyl (cPr)CH 2,4,6 -triCH 3 -phenyl 899 2-furanyl(cPr)CH 2,4,6 -triCH -phenyl 900 3-furan(cPr)CH 2,4,6 -triCH 3 -phenyl 901 2-thienyl(cPr)CH 2,4,6 -triCH 3 -phenyl 902 3-thienyl(cPr)CH 2,4,6 -triCH 3 -phenyl 903 2-isoxazolyl (cPr) CH 2,4,6 -triCH 3 -phenyl 904 2- (5-CH 3 -f uranyl) (cPr)CH 2,4,6 -triCH 3 -phenyl 905 2-(4-CH 3 -isoxazolyl) (cPr)CH 2,4,6 -triCH 3 -phenyl 906 cPr-CH(CH 3 ) 2,4,6 -triCH 3 -phenyl 907 l-cPr-CH(CH 2 CH 3 ) 2,4,6 -triCH 3 -phenyl 908 1-cPr-CH (CH 2 CH 2 CH 3 ) 2,4,6 -triCH 3 -phenyl 909 l-cPr-CH(CH 2 OCH 3 ) 2,4,6 -triCH 3 -phenyl 910 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2,4,6 -triCH 3 -phenyl 911 (cBu) 2 CH 2,4,6 -triCH 3 -phenyl 912 phenyl (cBu)CH 2,4,6 -triCH 3 -phenyl 913 2-furanyl(cBu)CH 2,4,6 -triCH 3 -phenyl 914 3-furan(cBu)CH 2,4,6 -triCH 3 -phenyl 915 2-thienyl(cBu)CH 2,4,6 -triCH 3 -phenyl 916 3-thienyl(cBu)CH 2,4,6 -triCH 3 -phenyl 917 2-isoxazolyl (cBu) CH 2,4,6 -triCH 3 -phenyl 918 2- (5-CH 3 -furanyl) (cBu)CH 2,4,6 -triCH 3 -phenyl 919 2-(4-CH 3 -isoxazolyl) (cBu)CH 2,4,6 -triCH 3 -phenyl 920 cBu-CH(CH 3 ) 2,4,6 -triCH 3 -phenyl 921 l-cBu-CH(CH 2 CH 3 ) 2,4,6 -triCH 3 -phenyl 922 1-cBu-CH (CH 2 CH 2 CH 3 ) 2,4,6 -triCH 3 -phenyl 923 l-cBu-CH(CH 2 OCH 3 ) 2,4,6 -triCH3-phenyl 924 1-cBu-CH (CH 2 CHOCH 3 ) 2, 4, 6-triCH 3 -phenyl 925 (cPr) 2 CH 2, 6-diMeO-pyrid-3-yl 926 phenyl (cPr)CH 2, 6-diMeO-pyrid-3-yl 927 2- furanyl (cPr)CH 2, 6-diMeO-pyrid-3-yl 928 3-furan(cPr)CH 2, 6-diMeO-pyrid-3-yl 929 2-thienyl(cPr)CH 2, 6-diMeO-pyrid-3-yl 930 3-thienyl(cPr)CH 2, 6-diMeO-pyrid-3-yl 931 2-isoxazolyl (cPr) CH 2, 6-diMeO-pyrid-3-yl 932 2- (5-CH 3 -furanyl) (cPr)CH 2, 6-diMeO-pyrid-3-yl 933 2-(4-CH 3 -isoxazolyl) (cPr)CH 2, 6-diMeO-pyrid-3-yl 934 cPr-CH(CH 3 ) 2, 6-diMeO-pyrid-3-yl 935 l-cPr-CH(CH 2 CH 3 ) 2, 6-diMeO-pyrid-3-yl 936 1-cPr-CH (CH 2 CH 2 CH 3 ) 2, 6-diMeO-pyrid-3-yl 937 l-cPr-CH(CH 2 OCH 3 ) 2, 6-diMeO-pyrid-3-yl 938 l-cPr-CH(CH 2 CH 2 OCH 3 ) 2, 6-diMeO-pyrid-3-yl 939 (cBu) 2 CH 2, 6-diMeO-pyrid-3-yl 940 phenyl (cBu)CH 2, 6-diMeO-pyrid-3-yl 941 2-furanyl (cBu)CH 2, 6-diMeO-pyrid-3-yl 942 3-furan(cBu)CH 2, 6-diMeO-pyrid-3-yl 943 2-thienyl (cBu)CH 2, 6-diMeO-pyrid-3-yl 944 3-thienyl(cBu)CH 2, 6-diMeO-pyrid-3-yl 945 2-isoxazolyl (cBu) CH 2, 6-diMeO-pyrid-3-yl 946 2- ( 5-CH 3 -furanyl) (cBu) CH 2, 6-diMeO-pyrid-3-yl 947 2-(4-CH 3 -isoxazolyl) (cBu)CH 2, 6-diMeO-pyrid-3-yl 948 cBu-CH(CH 3 ) 2, 6-diMeO-pyrid-3-yl 949 l-cBu-CH(CH 2 CH 3 ) 2, 6-diMeO-pyrid-3-yl 950 1-cBu-CH (CH 2 CH 2 CH 3 ) 2, 6-diMeO-pyrid-3-yl 951 l-cBu-CH(CH 2 OCH 3 ) 2, 6-diMeO-pyrid-3-yl 952 1-cBu-CH (CH 2 CH 2 OCH 3 ) 2, 6-diMeO-pyrid-3-yl 953 (cPr) 2 CH 2, 6-diCH 3 -pyrid-3-yl 954 phenyl (cPr)CH 2, 6-diCH3-pyrid-3-yl 955 2-furanyl (cPr) CH 2, 6-diCH 3 -pyrid-3-yl 956 3-furan(cPr)CH 2, 6-diCH 3 -pyrid-3-yl 957 2-thienyl(cPr)CH 2, 6-diCH 3 -pyrid-3-yl 958 3-thienyl(cPr)CH 2, 6-diCH 3 -pyrid-3-yl 959 2-isoxazolyl (cPr) CH 2, 6-diCH 3 -pyrid-3-yl 960 2- (5-CH 3 -furanyl) (cPr)CH 2, 6-diCH 3 -pyrid-3-yl 961 2-(4-CH 3 -isoxazolyl) (cPr)CH 2, 6-diCH 3 -pyrid-3-yl 962 cPr-CH(CH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 963 l-cPr-CH(CH 2 CH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 964 1-cPr-CH (CH 2 CH 2 CH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 965 l-cPr-CH(CH 2 OCH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 966 l-cPr-CH(CH 2 CH OCH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 967 (cBu) 2 CH 2 , 6-diCH 3 -pyrid-3-yl 968 phenyl (cBu)CH 2 , 6-diCH 3 -pyrid-3-yl 969 2- furanyl (cBu)CH 2 , 6-diCH 3 -pyrid-3-yl 970 3-furan(cBu)CH 2 , 6-diCH 3 -pyrid-3-yl 971 2-thienyl(cBu)CH 2 , 6-diCH 3 -pyrid-3-yl 972 3-thienyl(cBu)CH 2 , 6-diCH 3 -pyrid-3-yl 973 2-isoxazolyl (cBu) CH 2 , 6-diCH 3 -pyrid-3-yl 974 2- (5-CH 3 - furanyl) (cBu)CH 2 , 6-diCH 3 -pyrid-3-yl 975 2- (4-CH3- isoxazolyl) (cBu)CH 2 , 6-diCH 3 -pyrid-3-yl 976 cBu-CH(CH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 977 l-cBu-CH(CH 2 CH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 978 l-cBu-CH(CH 2 CH 2 CH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 979 l-cBu-CH(CH 2 OCH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 980 1-cBu-CH (CH 2 CH OCH 3 ) 2 , 6-diCH 3 -pyrid-3-yl 981 (cPr) 2 CH 2-CH 3 -6-MeO-pyrid-3-yl 982 phenyl (cPr)CH 2-CH 3 -6-MeO-pyrid-3-yl 983 2- furanyl (cPr)CH 2-CH 3 -6-MeO-pyrid-3-yl 984 3-furan(cPr)CH 2-CH 3 -6-MeO-pyrid-3-yl 985 2-thienyl(cPr)CH 2-CH 3 -6-MeO-pyrid-3-yl 986 3-thienyl(cPr)CH 2 -CH3- 6-MeO-pyrid-3 -yl 987 2-isoxazolyl (cPr) CH 2-CH 3 -6-MeO-pyrid-3-yl 988 2- (5-CH3- furanyl) (cPr)CH 2-CH 3 -6-MeO-pyrid-3-yl 989 2-(4-CH 3 -isoxazolyl) (cPr)CH 2-CH 3 -6-MeO-pyrid-3-yl 990 cPr-CH(CH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 991 l-cPr-CH(CH 2 CH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 992 1-cPr-CH (CH 2 CH 2 CH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 993 l-cPr-CH(CH 2 OCH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 994 1-cPr-CH (CH 2 CH 2 OCH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 995 (cBu) CH 2-CH 3 -6-MeO-pyrid-3-yl 996 phenyl (cBu)CH 2-CH 3 -6-MeO-pyrid-3-yl 997 2 - furanyl ( cBu) CH 2-CH 3 -6-MeO-pyrid-3-yl 998 3-furan(cBu)CH 2-CH 3 -6-MeO-pyrid-3-yl 999 2-thienyl(cBu)CH 2-CH 3 -6-MeO-pyrid-3-yl 1000 3-thienyl(cBu)CH 2-CH 3 -6-MeO-pyrid-3-yl 1001 2-isoxazolyl (cBu)CH 2-CH 3 -6-MeO-pyrid-3-yl 1002 2- (5-CH 3 -furanyl) (cBu)CH 2-CH 3 -6-MeO-pyrid-3-yl 1003 2-(4-CH 3 -isoxazolyl) (cBu)CH 2-CH 3 -6-MeO-pyrid-3-yl 1004 cBu-CH(CH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 1005 l-cBu-CH(CH 2 CH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 1006 l-cBu-CH(CH 2 CHCH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 1007 l-cBu-CH(CH 2 OCH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 1008 l-cBu-CH(CH 2 CH 2 OCH 3 ) 2-CH 3 -6-MeO-pyrid-3-yl 1009 (cPr) 2 CH 4-CH 3 -6-MeO-pyrid-3-yl 1010 phenyl (cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1011 2-furanyl (cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1012 3-furan(cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1013 2-thienyl(cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1014 3-thienyl(cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1015 2-isoxazolyl (cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1016 2- (5-CH 3 -furanyl ) (cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1017 2-(4-CH 3 -isoxazolyl) (cPr)CH 4-CH 3 -6-MeO-pyrid-3-yl 1018 cPr-CH(CH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1019 l-cPr-CH(CH 2 CH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1020 l-cPr-CH(CH 2 CH 2 CH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1021 l-cPr-CH(CH 2 OCH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1022 l-cPr-CH(CH 2 CH 2 OCH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1023 (cBu) 2 CH 4-CH 3 -6-MeO-pyrid-3-yl 1024 phenyl (cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1025 2-furanyl (cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1026 3-furan(cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1027 2-thienyl(cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1028 3-thienyl(cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1029 2-isoxazolyl (cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1030 2- (5-CH 3 -furanyl) (cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1031 2-(4-CH 3 -isoxazolyl) (cBu)CH 4-CH 3 -6-MeO-pyrid-3-yl 1032 cBu-CH(CH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1033 l-cBu-CH(CH 2 CH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1034 l-cBu-CH(CH 2 CH 2 CH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1035 l-cBu-CH(CH 2 OCH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1036 l-cBu-CH(CH 2 CH 2 OCH 3 ) 4-CH 3 -6-MeO-pyrid-3-yl 1037 (cPr) 2 CH 4-CH 3 -6- (CH 3 ) 2 N-pyrid-3-yl 1038 phenyl (cPr)CH 4-CH3-6- k CH 3 2 N-pyrid-3-yl 1039 2- f uranyl (cPr)CH 4-CH3-6- CH3 N-pyrid-3-yl 1040 3-furan(cPr)CH 4-CH3-6- CH 3 2 N-pyrid-3-yl 1041 2-thienyl(cPr)CH 4-CH3-6- :CH 3 2 N-pyrid-3-yl 1042 3-thienyl(cPr)CH 4-CH3-6- CH 3 N-pyrid-3-yl 1043 2-isoxazolyl (cPr)CH 4-CH3-6- CH 3 2 N-pyrid-3-yl 1044 2- (5-CH 3 - furanyl) (cPr)CH 4-CH3-6- .CH 3 2 N-pyrid-3-yl 1045 2-(4-CH 3 -isoxazolyl) (cPr)CH 4-CH 3 -6- CH 3 2 N-pyrid-3-yl 1046 cPr-CH(CH 3 ) 4-CH 3 -6- :CH 3 2 N-pyrid-3-yl 1047 l-cPr-CH(CH 2 CH 3 ) 4-CH 3 -6- ;CH 3 2 N-pyrid-3-yl 1048 1-cPr-CH (CH 2 CH 2 CH 3 ) 4-CH3-6- (CH 3 2 N-pyrid-3-yl 1049 l-cPr-CH(CH 2 OCH 3 ) 4-CH3-6- :CH 3 2 N-pyrid-3-yl 1050 1-cPr-CH (CH 2 CH 2 OCH 3 ) 4-CH 3 -6- ICH 3 2 N-pyrid-3-yl 1051 (cBu) 2 CH 4-CH3-6- (CH 3 2 N-pyrid-3-yl 1052 phenyl (cBu)CH 4-CH3-6- :CH 3 N-pyrid-3-yl 1053 2- furanyl (cBu)CH 4-CH3-6- (CH3 N-pyrid-3-yl 1054 3-furan(cBu)CH 4-CH3-6- (CH3 2 N-pyrid-3-yl 1055 2-thienyl(cBu)CH 4-CH3-6- (CH3 N-pyrid-3-yl 1056 3-thienyl(cBu)CH 4-CH3-6- (CH3 2 N-pyrid-3-yl 1057 2-isoxazolyl (cBu)CH 4-CH3-6- (CH3 N-pyrid-3-yl 1058 2- (5-CH3- furanyl) (cBu)CH 4-CH3-6- (CH3 2 N-pyrid-3-yl 1059 2-(4-CH 3 -isoxazolyl) (cBu)CH 4-CH3-6- (CH3 2 N-pyrid-3-yl 1060 cBu-CH(CH 3 ) 4-CH3-6- (CH3 2 N-pyrid-3-yl 1061 l-cBu-CH(CH 2 CH 3 ) 4-CH3-6- (CH3 ) 2 N-pyrid-3-yl 1062 1-cBu-CH (CH 2 CH 2 CH 3 ) 4-CH3-6- (CH 3 2 N-pyrid-3-yl 1063 l-cBu-CH(CH 2 OCH 3 ) 4-CH3-6- (CH 3 ) N-pyrid-3-yl 1064 1-cBu-CH (CH 2 CH 2 OCH 3 ) 4-CH3-6- (CH 3 ) 2 N-pyrid-3-yl UTILITY Compounds of this invention are expected to have utility in the treatment of inbalances associated with abnormal levels of CRF in patients suffering from depression, affective disorders, and/or anxiety. CRF-Rl Receptor Binding Assay for the Evaluation of Biological Ac ivi y The following is a description of the isolation of cell membranes containing cloned human CRF-Rl receptors for use in the standard binding assay as well as a description of the assay itself. Messenger RNA was isolated from human hippocampus . The mRNA was reverse transcribed using oligo (dt) 12-18 and the coding region was amplified by PCR from start to stop codons The resulting PCR fragment was cloned into the EcoRV site of pGEMV, from whence the insert was reclaimed using Xhol + Xbal and cloned into the Xhol + Xbal sites of vector pπβar ( which contains a CMV promoter, the SV40 't' splice and early poly A signals, an Epstein-Barr viral origin of replication, and a hygromycin selectable marker) . The resulting expression vector, called phchCRFR was transfected in 293EBNA cells and cells retaining the episome were selected in the presence of 400 μM hygromycin. Cells surviving 4 weeks of selection in hygromycin were pooled, adapted to growth in suspension and used to generate membranes for the binding assay described below. Individual aliquots containing approximately 1 x 10 8 of the suspended cells were then centrifuged to form a pellet and frozen. For the binding assay a frozen pellet described above containing 293EBNA cells transfected with hCRFRl receptors is homogenized in 10 ml of ice cold tissue buffer (50 mM HEPES buffer pH 7.0, containing 10 mM MgCl2, 2 mM EGTA, 1 μg/1 aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin) . The homogenate is centrifuged at 40,000 x g for 12 min and the resulting pellet rehomogenized in 10 ml of tissue buffer. After another centrifugation at 40,000 x g for 12 min, the pellet is resuspended to a protein concentration of 360 μg/ml to be used in the assay. Binding assays are performed in 96 well plates; each well having a 300 μl capacity. To each well is added 50 μl of test drug dilutions (final concentration of drugs range from 10-^0 - 10- 5 M) , 100 μl of 125 I-ovine-CRF ( 125 I-o-CRF) (final concentration 150 pM) and 150 μl of the cell homogenate described above. Plates are then allowed to incubate at room temperature for 2 hours before filtering the incubate over GF/F filters (presoaked with 0.3% polyethyleneimine) using an appropriate cell harvester. Filters are rinsed 2 times with ice cold assay buffer before removing individual filters and assessing them for radioactivity on a gamma counter. Curves of the inhibition of 12 5i-o-CRF binding to cell membranes at various dilutions of test drug are analyzed by the iterative curve fitting program LIGAND [P.J. Munson and D. Rodbard, Anal . Biochem. 107:220 (1980)], which provides Ki values for inhibition which are then used to assess biological activity. Alternatively, tissues and cells which naturally express CRF receptors can be employed in binding assays analogous to those described above. A compound is considered to be active if it has a Ki value of less than about 10000 nM for the inhibition of CRF. Inhibition of CRF-Sti ul t d Adenvlate Cvclase Activity Inhibition of CRF-stimulated adenylate cyclase activity can be performed as described by G. Battaglia et al. Synapse 1:572 (1987). Briefly, assays are carried out at 37° C for 10 min in 200 ml of buffer containing 100 mM Tris-HCl (pH 7.4 at 37° C) , 10 mM MgCl2, 0.4 mM EGTA, 0.1% BSA, 1 mM isobutylmethylxanthine (IBMX) , 250 units/ml phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5 ' -triphosphate, 100 nM oCRF, antagonist peptides (concentration range 10 ~ 9 to 10 ~ 6m) and 0.8 mg original wet weight tissue (approximately 40-60 mg protein) . Reactions are initiated by the addition of 1 mM ATP/[32p]ATP (approximately 2-4 Ci/tube) and terminated by the addition of 100 ml of 50 mM Tris-HCL, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 μl of [ 3 H]cAMP (approximately 40,000 dpm) is added to each tube prior to separation. The separation of [32p] C A P from [32p] TP is performed by sequential elution over Dowex and alumina columns. In vivo Biological Assay The in vivo activity of the compounds of the present invention can be assessed using any one of the biological assays available and accepted within the art. Illustrative of these tests include the Acoustic Startle Assay, the Stair Climbing Test, and the Chronic Administration Assay. These and other models useful for the testing of compounds of the present invention have been outlined in C.W. Berridge and A.J. Dunn Brain Research Reviews 15:71 (1990). Compounds may be tested in any species of rodent or small mammal. Dosage and Formul tion Compounds of this invention can be administered to treat these abnormalities by means that produce contact of the active agent with the agent's site of action in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. They can be administered alone, but will generally be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage administered will vary depending on the use and known factors such as pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and desired effect. For use in the treatment of said diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient of 0.002 to 200 mg/kg of body weight. Ordinarily, a dose of 0.01 to 10 mg/kg in divided doses one to four times a day, or in sustained release formulation will be effective in obtaining the desired pharmacological effect. Dosage forms (compositions) suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition. The active ingredient can be administered orally is solid dosage forms, such as capsules, tablets and powders; or in liquid forms such as elixirs, syrups, and/or suspensions . The compounds of this invention can also be administered parenterally in sterile liquid dose formulations . Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract. Liquid dose forms for oral administration can contain coloring or flavoring agents to increase patient acceptance. In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, butter substances. Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol . Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard reference in the field. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows : Capsules A large number of units capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate. Soft Gelatin Capsules, A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules were washed and dried. Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delayed adsorption. The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease. Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims: CLAIMS 1. A compound of formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof; wherein: D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 _ιo alkenyl, C 2 - 10 alkynyl, C 3 _ 8 cycloalkyl, C 3 _ 6 cycloalkyl-Cι- 6 alkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, -S0 2 -Cι_ιo alkyl, -S0 2 -R la , and -S0 2 -R lb ; 1 R is substituted with 1 or more substituents selected from the group -CN, -S(0) n R 14b , -CORl 3a , _ C o 2 Rl3 a -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16a , -NR 15 C0 2 R 1 b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 _g cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0- 1 substituents selected from the group R a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R 1 is also substituted with 1-3 substituents independently selected at each occurrence from the group R la , R lb , R l , Cι- 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, Cι_ 4 haloalkyl, -OR 13a , -NR 13a R 16a , C- 1 - 4 alkoxy-Cι- 4 alkyl and C 3 _ 8 cycloalkyl which is substituted with 0-1 R 9 and in which 0-1 carbons of C 4 _ 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R l is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R l being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 / -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17 R 19a , -NR 15a C0R 18 , -NR 17 R 19a , and -CONR 17 R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl, 2,3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cχ- 6 alkyl, C _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15 C0 2 R 18 , -NR 17a R 19a , and -CONR 17 R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from ,t_ ι he group C,,0„ 2τ R-,14b, ,C-,O~_R14b and-, S_,0_ 2τ R-,14b; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -COR 13a , -OC(0)R 14b , -NR 15a COR 13a , -N(COR 13a ) , -NR 15a CONR 13 R 16a , -NR 15a C0 2 R 1 b , -NR 13 R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R3a C0R 14b , COR 14b and S0 2 R 14b and wherein any su is optionally monooxidized or dioxidized; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl, - (CH 2 ) 1 - 4 -heteroaryl, or - (CH 2 ) ι_ 4 -heterocycle, wherein the aryl, heteroaryl, or heterocycle group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 3 _ 8 cycloalkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 Fs; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 _ 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, Cι_ 4 alkylsulfonyl, amino, C 1 - 4 alkyla ino, (C 1 - 4 alkyl ) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, Cχ_ 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C 1 - 6 alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Ci- 10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C3-6 cycloalkyl-C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, Cι_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 -6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, aryl, aryl(Cι_4 alkyl)-, heteroaryl and heteroaryl (Ci- 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1- 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 _ 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι-4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-Cι_ 6 alkyl, aryl, aryl (C1-4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group Cχ_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, Cι_ 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; Ri4b is selected from the group Cχ_ 4 alkyl, C 1 - 4 haloalkyl, C _ 4 alkoxy-Cι_ 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι_6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 _ 7 cycloalkyl, C 3 _ 6 cycloalkyl- Cι_ 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C _ 4 alkyl, Br, Cl, F, I, Cι_ 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 -. 4 alkyl, C 3 - 7 cycloalkyl, and C 3 _ 6 cycloalkyl-Cι_6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 -. 10 cycloalkyl, C 3 - 6 cycloalkyl-Cχ- 6 alkyl, C 1 - 2 alkoxy-Ci_ 2 alkyl, C- 1 - 4 haloalkyl, R 14 S (0) n -Ci- alkyl, and R 17b R 19b N-C 2- . 4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, C _ 2 alkoxy-Cι_ 2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; alternatively, in an NR ' R J moiety, R ' and R 1 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-ρiperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cι- 6 alkyl, C3_ιo cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl and C1-4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-C _ 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 / -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 Fs, OCF 3 , S0 2 Me and acetyl; heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2,3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cχ- 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14 , COR 14a and S0 2 R 14 ; and, provided that when D is imidazole or triazole, R 1 is other than unsubstituted Cι- 6 linear or branched alkyl or C 3 -6 cycloalkyl. 2. A compound according to Claim 1, wherein: R 1 is selected from C 3 -8 cycloalkyl and C3-6 cycloalkyl-Cι-6 alkyl. 3. A compound according to Claim 1 , wherein : D is a heteroaryl group attached through an unsaturated carbon atom. 4. A compound according to Claim 1, wherein: D is a phenyl group substituted with 3-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 -6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R lo \ -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group Cι_ 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 Fs, OCF 3 , S0 2 Me and acetyl. 5. A compound according to Claim 1, wherein: R is Ci- 10 alkyl; and R is substituted with 1-3 substituents selected from the group R la , R lb , R lc , C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -OR 13a , -NR 13a R 16a , -CN, -S(0) n R 1 b , -COR 13 , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13 R 16a , -NR 15a C0 2 R 1 b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl wherein the N 4 in the 1-piperazinyl is substituted with 0-1 substituents selected from the group R a , C0 2 R COR 14b and S0 2 R 14b ; C 3 _ 8 cycloalkyl wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR ,13a -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -; and C 3 - 8 cycloalkyl wherein the C 3 _s cycloalkyl is substituted wwiitthh 00--11 RR 9 ,, aanncd 0-1 carbons in the C 3 - 8 cycloalkyl is replaced by -0- 6. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Ci- 10 alkyl, C 2 -ιo alkenyl, C 2 _ιo alkynyl, C 3 _ 8 cycloalkyl, C 3 .- 6 cycloalkyl-Cι_ 6 alkyl, C 1 - 4 alkoxy-Cι_ alkyl, -SO 2 -Cι_ι 0 alkyl, -S0 2 -R la , and -S0 2 -R lb ; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 1 , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 1 b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 _ 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13 -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R l , R lb , R lc , C 1 - 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, Cι_ 4 haloalkyl, -OR 13a , -NR 13 R 16a , and C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 _8 cycloalkyl is replaced by -0-; provided that R 1 is other than a 1-cyclopropyl-3- methoxypropyl group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 1 COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19 , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl, benzoxazolyl , isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Ci-e alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, Cι- 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R , C0 2 R , COR and S0 2 R ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Ci-e alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13 , SH, -S(0) n R 1 b , -COR 13 , -OC(0)R 14b , -NR 15a COR 13a , -N(COR 13 ) 2 , -NR 15a CONR 13 R 16a , -NR 15a C0 2 R 14b , -NR 13 R 16a , and -CONR 13a R 16 and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R ,13a C0 2 R 1 b , COR 14b and S0 2 R 14b and wherein any st is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C _ 8 cycloalkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-3 substituents selected from the group hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 Fs; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, Ci-e alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Ci-10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 6 alkyl, aryl, aryl(Cι-4 alkyl)-, heteroaryl and heteroaryl (Cι_ 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 _ 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 -4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 _ 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, aryl, aryl (Cι_ 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, Cι_ 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 _ 6 cycloalkyl-Cι-6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, C3-6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, Cι_6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Ci-e alkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 7 R moiety, R 7 and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0R 14 , COR 14 and S0R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cχ-6 alkyl, C3- 10 cycloalkyl, C 3 .- 6 cycloalkyl-Cι-6 alkyl and C1-4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, Cι_ haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 Fs, OCF 3 , S0 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 .- 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents sele icctteed from the group R 15 , C0 2 R 14a , COR 14 and S0 2 R 1 J 4a 7. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 _ιo alkenyl, C2-10 alkynyl, C3-8 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, -S0 2 -Cι_ιo alkyl, -S0 2 -R la , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 1 b , -COR 13a , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13 ) 2 , -NR 15a CONR 13a R 16a , -NR 15 C0 2 R 1 b , -CONR 13a R 16 , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C4-8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14b , COR 14b and S0 2 R 14b ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Ci-e alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, Cι- 4 haloalkyl, -OR 13a , -NR 13 R 16a , and C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a 1-cyclopropyl-3- methoxypropyl group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 1 a C0R 18 , -NR 17a R 19a , and -C0NR 17a R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl , benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C1- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Cι- 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)π,R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15 C0 2 R 18 , -NR 17a R 19a , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from * t--h u e group π R15a, C,.,0_ 2π R14b, C_,O„ r R,14b a ^^ nd-, S„0„ 2n R14b; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C _ 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 1 b , -COR 13a , -OC(0)R 14b , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13 R 16a , -NR 15 C0 2 R 14b , -NR 13 R 16a , and -CONR 13 R 16 and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C 3 _ 8 cycloalkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-3 substituents selected from the group hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ,- R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 _ 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 _ 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, C 1 - 4 alkylthio, C1-4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, Cχ- 6 alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Ci- 10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, Cι_ 4 alkyl and C 3 _ 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, Cι_ 4 alkoxy-Cι- 4 alkyl, C 3 _ 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)-; R 13a and R 16 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-C - 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, aryl, aryKCι-4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, Cι_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 - 4 alkyl, Cχ_ 4 haloalkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, C 3 - 6 cycloalkyl, and C 3 _ 6 cycloalkyl-Cι_6 alkyl; R 15 is independently selected at each occurrence from the group H, Cι- 4 alkyl, C3-7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group Cχ_ 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C1-6 alkyl, C 3 _ιo cycloalkyl, C3-6 cycloalkyl-C -e alkyl, C1-2 alkoxy-Cι_ 2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Ci-β alkyl, C3-10 cycloalkyl, C 3 --6 cycloalkyl-Cι- 6 alkyl and C 1 -4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, Cχ_ 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I,. -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , S0 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl , benzoxazolyl , isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Cι_ 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selescctteed from the group R , C0R a , COR a and ,14a S0 2 R J 8. A compound according to Claim 1, wherein the compound is selected from: 1- (1-ethyl ) propyl-2-ethyl-4- (2,4,5-trichlorophenyl ) -1H- benzimidazole, 1- (1-ethyl) propyl-2-methoxy-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-methyl) butyl-2-ethyl-4- (2 , 4, 5-trichlorophenyl) -7-methyl- lH-benzimidazole, 1- (1-methyl )butyl-2-methyl-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-methyl) butyl-2-methoxy-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-butyl) -2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1-carbmethoxy) propyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, l-(l-carbethoxy)ethyl-2-ethyl-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1, l-Dicyclopropyl)methyl-2-ethyl-4- (2, 4, 5-trichlorophenyl) - lH-benzimidazole, 1- (1, l-Dicyclopropyl)methyl-2-methoxy-4- (2,4,5- trichlorophenyl) -lH-benzimidazole, 1- (1-cyclopropyl) propyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, l-cyclopentyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -lH- benzimidazole, l-cyclopentyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -6-methyl-lH- benzimidazole, 1- (1-phenyl) propyl-2-ethyl-4- (2,4, 5-trichlorophenyl) -1H- benzimidazole, 1- (1, l-diphenyl)methyl-2-ethyl-4- (2, 4, 5-trichlorophenyl) -1H- benzimidazole, l-cyclopentyl-2-ethyl-4- (2,4, 6-trimethylphenyl )benzimidazole, 1- (2-methyl )cyclopentyl-2-ethyl-4- (2,4, 6-trimethylphenyl) -1H- benzimidazole, 1- (1, 1-dicyclopropyl)methyl-2-ethyl-4- (2,4, 6-trichlorophenyl) - lH-benzimidazole, 1- (1, 1-dicyclopropyl)methyl-2-ethyl-4- (2, 4-dichlorophenyl) -1H- benzimidazole, 1- (1, 1-dicyclopropyl)methyl-2-ethyl-4- (2-methyl-4- methoxyphenyl) -lH-benzimidazole, 1- (1-cyclopropyl) butyl-2-ethyl-4- (2-methyl-4-methoxyphenyl) - IH- benzimidazole, 1- (3-pentyl ) -2-ethyl-4- (2 , 4-dimethyl-5-fluorophenyl) -1H- benzimidazole, l-(2-pentyl)-2-ethyl-4- (2, 4-dimethyl-5-fluorophenyl) -1H- benzimidazole, 1- (2-methyl) butyl-2-ethyl-4- (2, 4-dichloro-5-fluorophenyl) -1H- benzimidazole, and l-cyclopentyl-2-ethyl-4-(2,4,6-trimethyl-3-pyridyl)-lH- benzimidazole.

Inventors: BECK JAMES P, CURRY MATTHEW A, BECK, JAMES, P., CURRY, MATTHEW, A.
Applicants: DU PONT PHARM CO, DU PONT PHARMACEUTICALS COMPANY
Application year: 1999
Main classification: C07D235
IPC codes: C07D235, C07D401, C07D403, C07D405, C07D409